| page | |
| Oral session | |
| Clinical Respiratory Medicine 1 | |
| 4 | O1-1: The 1-minute sit-to-stand test to help detect exertional desaturation during the 6-minute walk test in interstitial lung disease patients with normal resting blood oxygen levels
10.1111/resp.14149 |
| 4 | O1-2: Protein C activity as a potential prognostic factor for nursing home-acquired pneumonia
10.1111/resp.14149_2 |
| 5 | O1-3: Lung volume recruitment therapy in people with neuromuscular disease
10.1111/resp.14149_3 |
| 5 | O1-4: Prognosis of Japanese patients with late-onset non-infectious pulmonary complications after hematopoietic stem cell transplantation registered for lung transplantation
10.1111/resp.14149_4 |
| 6 | O1-5: A gentlemen with exertional dyspnea following allogenic bone marrow transplantation (BMT): A case report of chronic pulmonary graft versus host disease (GVHD) manifest as bronchiectasis:
10.1111/resp.14149_5 |
| Clinical Respiratory Medicine 2 | |
| 6 | O2-1: Elevated levels of induced-sputum IL-36 gamma and osteopontin in the elderly with dysphagia
10.1111/resp.14149_7 |
| 7 | O2-2: Development and implementation of an aspiration pneumonia diagnostic algorithm for the practical application of the JRS guidelines
10.1111/resp.14149_8 |
| 8 | O2-3: Novel non-invasive point of care sputum test for early identification of Pseudomonas aeruginosa airway infection
10.1111/resp.14149_9 |
| 8 | O2-4: Prevalence, characteristics, risk factors and disease course of ulcerative colitis-related pulmonary manifestations
10.1111/resp.14149_10 |
| 9 | O2-5: Impacts of nebulised GM-CSF treatment in autoimmune pulmonary alveolar proteinosis: A systematic review and meta-analysis
10.1111/resp.14149_11 |
| Cell and Molecular Biology | |
| 9 | O3-1: Role of reactive persulfide species in influenza virus-induced lung inflammation
10.1111/resp.14149_13 |
| 10 | O3-2: Transplantation of lung progenitors derived from human induced pluripotent stem cells into the murine lungs
10.1111/resp.14149_14 |
| 10 | O3-3: miR-21 regulates the proliferation and apoptosis of human bronchial epithelial cells by targeting PARP-1
10.1111/resp.14149_15 |
| 11 | O3-4: In-silico cross-validation unveiled genomic mortality signatures of CC5 and CC8 MRSA obtained from the intensive care patients
10.1111/resp.14149_16 |
| 11 | O3-5: Fast AI-enabled cell tracking and migration analysis for high-throughput drug screening
10.1111/resp.14149_17 |
| 12 | O3-6: The Pulmonary Endothelium Plays a Critical Role in the Fibrotic Response to Lung Injury through S1PR1 and ROCK Mediated Cytoskeletal Rearrangements
10.1111/resp.14149_18 |
| Clinical Allergy and Immunology | |
| 12 | O4-1: Reactive sulfur species are involved in the regulation of innate immunity of type 2 airway inflammation
10.1111/resp.14149_20 |
| 13 | O4-2: Serum albumin in furry animals as a cross-reactive component may cause more severe allergic symptoms
10.1111/resp.14149_21 |
| 14 | O4-3: Deletion of ELOVL fatty acid elongase 6 (Elovl6) aggravates allergic airway inflammation through promoting the ceramide and sphingosine-1-phosphate signaling pathway
10.1111/resp.14149_22 |
| 14 | O4-4: A synthetic oligonucleotide consisting of a poly-guanosine sequence suppresses phytohemagglutinin-induced IL-10 from human peripheral blood mononuclear cells
10.1111/resp.14149_23 |
| 14 | O4-5: Combination of tryptase and IL-33 in bronchoalveolar lavage fluid may predict the types of eosinophilic pneumonia and disease recurrence
10.1111/resp.14149_24 |
| Environmental and Occupational Health and Epidemiology | |
| 15 | O5-1: The peak expiratory flow rate and respiratory health of children 7 to 18 years-old living near the Inayawan Landfill Site, Cebu City, Philippines
10.1111/resp.14149_26 |
| 15 | O5-2: Factors affecting compliance to COVID-19 infection prevention and control measures and its effects on the risk of COVID-19 infection among physicians in a tertiary government hospital
10.1111/resp.14149_27 |
| 16 | O5-3: Traffic-related air pollution and respiratory health: A cross-sectional study among adolescents in Vietnam
10.1111/resp.14149_28 |
| 16 | O5-4: The effects of smoking cessation therapy on pulmonary function and predictive factor of the FEV1 increase
10.1111/resp.14149_29 |
| 16 | O5-5: Current smoking by socioeconomic status in a representative Japanese population
10.1111/resp.14149_30 |
| Respiratory Infections (non-tuberculous) 1 | |
| 17 | O6-1: A multi-epitope peptide rOmp22 encapsulated in chitosan-PLGA nanoparticles as vaccine candidate against Acinetobacter baumannii infection
10.1111/resp.14149_32 |
| 18 | O6-2: A novel broad-spectrum peptide therapy for acute and chronic lung infections with multidrug-resistant gram-negative bacteria
10.1111/resp.14149_33 |
| 18 | O6-3: Bioinformatics analysis of high-throughput sequencing to identify key genes and signaling pathways in vero E6 cells infected by SARS-CoV-2
10.1111/resp.14149_34 |
| 19 | O6-4: Treatment outcomes of COVID-19 patients in Hong Kong's first designated infection control centre and the impact of emergent SARS-CoV-2 mutant strains from imported cases
10.1111/resp.14149_35 |
| 19 | O6-5: Genome-wide association study in patients with pulmonary Mycobacterium avium complex disease
10.1111/resp.14149_36 |
| Respiratory Infections (non-tuberculous) 2 | |
| 20 | O7-1: Structural differentiation of the spike glycoprotein from SARS-CoV-2 COVID-19 variants of concern compared to other human-infecting coronaviruses: A computational study with clinical implications
10.1111/resp.14149_38 |
| 20 | O7-2: Subunit immunization with outer membrane protein potentially protects broadly against multidrug-resistant gram-negative bacillus
10.1111/resp.14149_39 |
| 20 | O7-3: A potential novel prognostic sputum biomarker for chronic Pseudomonas aeruginosa biofilm pulmonary infection
10.1111/resp.14149_40 |
| 21 | O7-4: Early life respiratory infections perturb lung function in adulthood
10.1111/resp.14149_41 |
| 21 | O7-5: The role of increasing TIM3 on T cells in patients with nontuberculous mycobacterial lung disease: From immune cell dysfunction to clinical severity
10.1111/resp.14149_42 |
| Respiratory Infections (non-tuberculous) 3 | |
| 22 | O8-1: Microbiology and treatment outcomes of pleural infection in a tertiary hospital in Hong Kong: A 10-year review
10.1111/resp.14149_44 |
| 22 | O8-2: Clinical impact by phenotyping empyema based on pleural fluid culture positivity and appearance: A 7-year retrospective analysis
10.1111/resp.14149_45 |
| 23 | O8-3: The effectiveness of the combined use of remdesivir and regdanvimab (CT-P59) in patients with severe COVID-19: A single center retrospective study
10.1111/resp.14149_46 |
| 24 | O8-4: Determination of antibody titers of filipino healthcare workers after COVID-19 vaccination (Sinovac and Astrazenica) - A preliminary report
10.1111/resp.14149_47 |
| 25 | O8-5: Prevalence of acute myocardial injury among COVID-19 patients in Persahabatan Hospital, Jakarta
10.1111/resp.14149_48 |
| Tuberculosis 1 | |
| 25 | O9-1: A Major systemic drug reaction under 1HP tuberculosis prevention in non-HIV population:
10.1111/resp.14149_50 |
| 25 | O9-2: Gut microbiota signature can distinguish latent TB infection among poorly diabetic patients
10.1111/resp.14149_51 |
| 26 | O9-3: Artificial intelligence-assisted pathological screening of acid-fast bacilli may be useful for early detection of mycobacteriosis:
10.1111/resp.14149_52 |
| 26 | O9-4: The effects of active hexose correlated compound (AHCC) on levels of CD4+ and CD8+ in human immunodeficiency virus (HIV) infected tuberculosis patients:
10.1111/resp.14149_53 |
| 27 | O9-5: Factors affecting time to sputum culture conversion with drug resistant tuberculosis using short-term and longer regimen in Indonesia
10.1111/resp.14149_54 |
| Tuberculosis 2 | |
| 27 | O10-1: Community-led tuberculosis and COVID-19 risk communication in the Vietnamese migrant population in Japan
10.1111/resp.14149_56 |
| 28 | O10-2: Collaboration of professional organization as public-private mix practice in tuberculosis control in Padang City, West Sumatera
10.1111/resp.14149_57 |
| 28 | O10-3: Echographic septation: A useful diagnostic indicator discriminating tuberculous from malignant pleural effusion
10.1111/resp.14149_58 |
| 29 | O10-4: Effectiveness of intravenous isoniazid and ethambutol administration in patients with drug-susceptible pulmonary tuberculosis with TB-meningoencephalitis and HIV co-infection in the intensive phase of treatment
10.1111/resp.14149_59 |
| 29 | O10-5: Usage of addictive agents and alcohol among patients infected with tuberculosis
10.1111/resp.14149_60 |
| COPD 1 | |
| 30 | O11-1: Siglec-1-negative alveolar macrophages are associated with COPD exacerbation and may represent pro-inflammatory phenotypes
10.1111/resp.14149_62 |
| 30 | O11-2: Anomalous epithelial variations and ectopic inflammatory response in chronic obstructive pulmonary disease
10.1111/resp.14149_63 |
| 31 | O11-3: Risk factors of rapid lung function decline in COPD patients of real world
10.1111/resp.14149_64 |
| 31 | O11-4: Association of preserved ratio impaired spirometry with mortality risk: The Hisayama study
10.1111/resp.14149_65 |
| 32 | O11-5: IVC 'MIS'-guided fluids? An evaluation of the effect of different peep on the IVC indices of COPD patients on NIV
10.1111/resp.14149_66 |
| COPD 2 | |
| 32 | O12-1: Pulmonary hyperinflation and the risk of COPD exacerbation: Analysis from KOCOSS cohort
10.1111/resp.14149_68 |
| 33 | O12-2: Effectiveness of empirical anti-pseudomonal antibiotics in recurrent COPD exacerbation: A multicenter retrospective cohort study
10.1111/resp.14149_69 |
| 33 | O12-3: Epithelial mesenchymal transition (EMT) is an active process in smokers, patients with small airway disease and COPD: Implications for small airway fibrosis and obliteration
10.1111/resp.14149_70 |
| 33 | O12-4: Comprehensive analysis of allergen-specific IGE in COPD: Mite-specific IGE specifically related to the diagnosis of asthma-COPD overlap
10.1111/resp.14149_71 |
| 34 | O12-5: Insulin-resistance as an activator of inflammation in the comorbid course of сhronic obstructive pulmonary disease and metabolic syndrome
10.1111/resp.14149_72 |
| Lung Cancer 1 | |
| 35 | O13-1: High PD-L1 expression influenced the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small-cell lung cancer patients
10.1111/resp.14149_74 |
| 36 | O13-2: Two year follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater
10.1111/resp.14149_75 |
| 36 | O13-3: The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
10.1111/resp.14149_76 |
| 36 | O13-4: Comprehensive analysis of aquaporin superfamily in lung adenocarcinoma
10.1111/resp.14149_77 |
| 37 | O13-5: The characteristic of acquired resistance (T790M MUTATION) using plasma ct-DNA in EGFR-TKI treatment of adenocarcinoma lung patients
10.1111/resp.14149_78 |
| Lung Cancer 2 | |
| 37 | O14-1: Comparing effectiveness of FDA approved first-line treatments for patients with advanced NSCLC and high PD-L1 expression
10.1111/resp.14149_80 |
| 38 | O14-2: Chemotherapy versus chemo-immunotherapy as first-line treatment in patients with extensive-stage small-cell lung cancer-A systematic review and meta-analysis
10.1111/resp.14149_81 |
| 39 | O14-3: Diagnostic and dynamic circulating methylated DNA markers for non-small cell lung cancer
10.1111/resp.14149_82 |
| 39 | O14-4: Immunological contribution in the development of lung cancer with pulmonary fibrosis
10.1111/resp.14149_83 |
| 40 | O14-5: Pulmonologists and molecular biomarker testing for patients with advanced non-small cell lung cancer
10.1111/resp.14149_84 |
| Lung Cancer 3 | |
| 40 | O15-1: Evaluation of CXCL12 expression in the microenvironment of non-small cell lung cancer
10.1111/resp.14149_86 |
| 40 | O15-2: Comparison of treatment duration in developing drug resistance to EGFR-TKI, pemetrexed, and combination treatment in NSCLC in vitro
10.1111/resp.14149_87 |
| 41 | O15-3: The immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer
10.1111/resp.14149_88 |
| 41 | O15-4: The efficacy of gefitinib as a first-line therapy in elderly patients with advanced non-small cell lung cancer with EGFR mutations
10.1111/resp.14149_89 |
| 42 | O15-5: Relationship between PD-L1 expression, common driver mutations and cigarette smoking in patients with non-small cell lung cancer
10.1111/resp.14149_90 |
| Asthma 1 | |
| 42 | O16-1: Intergenerational effects of passive smoking in fathers on offspring's asthma: A longitudinal cohort study
10.1111/resp.14149_92 |
| 43 | O16-2: The role of 27-hydroxycholesterol in the pathogenesis of bronchial asthma
10.1111/resp.14149_93 |
| 43 | O16-3: Incidence and risk factors of recurrence/flares of allergic bronchopulmonary mycosis
10.1111/resp.14149_94 |
| 44 | O16-4: Grape seed proanthocyanidin extract ameliorates glucocorticoid insensitivity in severe asthma
10.1111/resp.14149_95 |
| 44 | O16-5: Asthma persistence is associated with gender, age and inhaled corticosteroid treatment and history of disease exacerbations in Chinese children
10.1111/resp.14149_96 |
| Asthma 2 | |
| 45 | O17-1: Asthma status during COVID-19 pandemic
10.1111/resp.14149_98 |
| 45 | O17-2: Performance of GINA score against ACT in defining asthma control and predicting unplanned healthcare utilization
10.1111/resp.14149_99 |
| 46 | O17-3: Reasons for uncontrolled asthma in patients attending a difficult-to-treat asthma clinic
10.1111/resp.14149_100 |
| 46 | O17-4: Novel predictive biomarkers for mepolizumab treatment in patients with severe asthma
10.1111/resp.14149_101 |
| 47 | O17-5: Soluble TIM-4 levels in serum are associated with severe asthma phenotype
10.1111/resp.14149_102 |
| Respiratory Neurobiology and Sleep | |
| 47 | O18-1: Information-motivation-behavioral skills intervention increases the CPAP adherence in old OSAHS patients
10.1111/resp.14149_104 |
| 48 | O18-2: Breathing irregularities before sleep onset on polysomnography in patients with heart diseases
10.1111/resp.14149_105 |
| 48 | O18-3: Analysis of nocturnal desaturation waveform by using algorithm in the patients with idiopathic pulmonary fibrosis
10.1111/resp.14149_106 |
| 49 | O18-4: Non-invasive ventilation improves persistent tachycardia in a case of mitochondrial myopathy
10.1111/resp.14149_107 |
| 49 | O18-5: Sleep apnea and academic performance: A study on medical students using the Berlin questionnaire
10.1111/resp.14149_108 |
| Critical Care Medicine | |
| 49 | O19-1: Non-invasive ventilation vs early intubation for acute hypoxaemic respiratory failure: A single-centre propensity-matched cohort study
10.1111/resp.14149_110 |
| 50 | O19-2: Clinical utility of serum heme oxygenase-1 for evaluating oxidative stress in patients with lung injury
10.1111/resp.14149_111 |
| 50 | O19-3: The outcomes of evolving treatment regimens among COVID-19 Confirmed severe and critical cases admitted at the lung center of the Philippines
10.1111/resp.14149_112 |
| 51 | O19-4: Pilot mobile assisted ventilation services (MOVES) in acute general medical wards (AGMW) during winter surge in QEH
10.1111/resp.14149_113 |
| 51 | O19-5: Sepsis, cardiovascular events and short-term mortality risk in critically ill patients
10.1111/resp.14149_114 |
| Bronchoscopy and Interventional Techniques | |
| 52 | O20-1: Spinal cord infarction after bronchial artery embolization using coils for hemoptysis: A single-center retrospective analysis of 3046 procedures
10.1111/resp.14149_116 |
| 52 | O20-2: Validation of factors make cryobiopsy more effective for peripheral pulmonary lesions: Results of the Minerva Registry
10.1111/resp.14149_117 |
| 53 | O20-3: Multiple pulmonary function measurement system for guiding interventional bronchoscopy
10.1111/resp.14149_118 |
| 53 | O20-4: Diagnostic yield and the number of tumor cells of ultrathin bronchoscopy for peripheral lung lesions: A comparison with thin bronchoscopy
10.1111/resp.14149_119 |
| 54 | O20-5: The microbiology of postobstructive pneumonia in patients with malignancy endo-bronchial lesions
10.1111/resp.14149_120 |
| Paediatric Lung Disease | |
| 54 | O21-1: Pediatric lung transplantation in Korea: A single center experience
10.1111/resp.14149_122 |
| 55 | O21-2: Relationship between wheezing and developmental trajectory of nasopharyngeal microbiome in Chinese toddlers
10.1111/resp.14149_123 |
| 55 | O21-3: Comparing admission days of tracheostomized children admitted with bTARTIs 6-month before and after home respiratory care training
10.1111/resp.14149_124 |
| 56 | O21-4: A case report of bronchiolitis obliterans in a child post hydrocarbon inhalation in Angkor Hospital for Children
10.1111/resp.14149_125 |
| 56 | O21-5: Bronchiolitis obliterans in an asthmatic diagnosed child at the chest clinic, Angkor Hospital for children
10.1111/resp.14149_126 |
| Respiratory Structure and Function | |
| 56 | O22-1: Parenchymal destruction in asthma: Fixed airflow obstruction and lung function trajectory
10.1111/resp.14149_128 |
| 57 | O22-2: Oscillometry in single lung transplantation for interstitial lung disease demonstrates abnormal respiratory reactance: results of a multi-center cross-sectional study
10.1111/resp.14149_129 |
| 58 | O22-3: Cohort differences in spirometry indices in healthy Singapore Chinese adults
10.1111/resp.14149_130 |
| 58 | O22-4: Dynamic-forced expiratory CT as a useful protocol for severe ECAC
10.1111/resp.14149_131 |
| 59 | O22-5: Complete pulmonary function profiles of 267 post COVID patients with exertional dyspnea in Bangladesh
10.1111/resp.14149_132 |
| Pulmonary Circulation | |
| 60 | O23-1: Clinical features of novel phenotype in pulmonary hypertension along with mild lung parenchymal change without severe ventilatory impairment
10.1111/resp.14149_134 |
| 60 | O23-2: Clinical characteristics of pulmonary arterial hypertension and co-existing lung disease: Analysis of the data from National Research Project of Intractable Disease in Japan
10.1111/resp.14149_135 |
| 61 | O23-3: Elevated betaine is associated with poor prognosis of patients with pulmonary hypertension
10.1111/resp.14149_136 |
| 61 | O23-4: An elusive cause of dyspnea
10.1111/resp.14149_137 |
| 62 | O23-5: Taiwan cohort - Registry of chronic thromboembolic pulmonary hypertension (TREC): A preliminary study
10.1111/resp.14149_138 |
| Interstitial Lung Disease | |
| 62 | O24-1: Regulation of SMAD7 and SOCS1 through metabolic and epigenetics coordination by mesenchymal stem cell-derived humoral factor STC1 induces anti-fibrotic and anti-inflammatory effects in lung injuries
10.1111/resp.14149_140 |
| 63 | O24-2: The role of circulatory high-mobility group box 1 for predicting checkpoint inhibitor pneumonitis caused by anti-PD-1/PD-L1 antibody monotherapy
10.1111/resp.14149_141 |
| 64 | O24-3: The role of mitochondria-dependent metabolic reprogramming in the pathogenesis of pulmonary fibrosis
10.1111/resp.14149_142 |
| 64 | O24-4: Impact of medication burden on tolerability of disease-targeted therapy and survival in interstitial lung disease
10.1111/resp.14149_143 |
| 65 | O24-5: Altered megakaryocyte and platelet parameters in idiopathic pulmonary fibrosis
10.1111/resp.14149_144 |
| 65 | O25-1: Increased expression of angiotensin-converting enzyme 2 (ACE2), TMPRSS2 and furin in idiopathic pulmonary fibrosis (IPF) and lymphangioleiomyomatosis (LAM) patients' lung tissue: Implications for COVID -19
10.1111/resp.14149_146 |
| 66 | O25-2: Assessment of alveolar-capillary membrane permeability using aerosol scintigraphy in diffuse cutaneous systemic sclerosis – A cross sectional study
10.1111/resp.14149_147 |
| 66 | O25-3: Clinical characteristics in patients who clinically diagnosed with idiopathic pleuroparenchymal fibroelastosis using new Japanese clinical diagnostic criteria
10.1111/resp.14149_148 |
| 67 | O25-4: A real-world study of the safety and efficacy of low-dose nintedanib for idiopathic pulmonary fibrosis
10.1111/resp.14149_149 |
| 67 | O25-5: The end of the road for patients with interstitial lung disease, are we doing enough?
10.1111/resp.14149_150 |
| Poster Session | |
| Clinical Respiratory Medicine | |
| 69 | P1-1: Role of early intrapleural fibrinolytic therapy for thoracic empyema: An analysis of the nationwide inpatient database
10.1111/resp.14150 |
| 69 | P1-2: Correlations in physical symptoms, blood biochemical findings, and chest ct images in an early phase of COVID-19 patient
10.1111/resp.14150_2 |
| 70 | P1-3: Prescribing oxygen: An audit of prescribing and delivery practices at two tertiary hospitals in Melbourne, Australia
10.1111/resp.14150_3 |
| 70 | P1-4: Computed tomographic volumetry in the diagnosis of lung inflation disorders in patients with pulmonary-mediastinal sarcoidosis
10.1111/resp.14150_4 |
| 71 | P1-5: The cytokine balance of allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA)
10.1111/resp.14150_5 |
| 72 | P1-6: Clinical effectiveness of cefoperazone-sulbactam versus piperacillin-tazobactam for the treatment of pneumonia in the elderly population
10.1111/resp.14150_6 |
| 72 | P1-7: Withdrawn
10.1111/resp.14150_7 |
| 72 | P1-8: Impact on inhalation adherence of asthma and COPD patients during the COVID-19 pandemic
10.1111/resp.14150_8 |
| 73 | P1-9: Predictive factor of high-flow nasal oxygen failure in COVID-19 patients at tertiary hospital in Jakarta
10.1111/resp.14150_9 |
| 73 | P1-10: Indicators of the pituitary-thyroid system in asthma patients with cold airway hyperresponsiveness without manifestation of thyroid lesion, living in endemic goiter area
10.1111/resp.14150_10 |
| 73 | P1-11: Acute pulmonary complications following cosmetic silicone breast injections: 2 rare cases
10.1111/resp.14150_11 |
| 74 | P1-12: Eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome) presenting as acute polyneuropathy mimicking Guillain-Barre syndrome - A case report
10.1111/resp.14150_12 |
| 75 | P1-13: Effect of bromhexine among COVID-19 patients - A meta-analysis
10.1111/resp.14150_13 |
| 75 | P1-14: Venous blood gases versus arterial blood gases in the titration of acute non-invasive ventilation
10.1111/resp.14150_14 |
| 76 | P1-15: Chest X-ray improvement in COVID-19 moderate symptoms with remdesvir and favipiravir: A comparative study
10.1111/resp.14150_15 |
| 76 | P1-16: VAP bundle for chronic ventilator ward patients in TB and chest unit of Grantham Hospital
10.1111/resp.14150_16 |
| 76 | P1-17: A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure
10.1111/resp.14150_17 |
| 77 | P1-18: Whole-lung lavage for pulmonary alveolar proteinosis in Australia – Safety and efficacy at a single centre
10.1111/resp.14150_18 |
| 77 | P1-19: Thoracic endometriosis diagnosed with the aid of the pleuroscopy
10.1111/resp.14150_19 |
| 78 | P1-20: Adulthood presentation of congenital pulmonary airway malformation type-1
10.1111/resp.14150_20 |
| 78 | P1-21: The effectiveness of 5 days antibiotic therapy on patients hospitalized for community acquired pneumonia
10.1111/resp.14150_21 |
| 79 | P1-22: The prevalence and clinical significance of pleural fluid detected by chest MRI: A cross-sectional study in a medical checkup setting
10.1111/resp.14150_22 |
| 79 | P1-23: Effects of early nutrition therapy combined with early pulmonary rehabilitation on ADL performance in elderly patients with pneumonia
10.1111/resp.14150_23 |
| 80 | P1-24: Correlation of chest CT findings and severity of coronavirus disease (COVID-19) infections in patients admitted at Chinese General Hospital and Medical Center
10.1111/resp.14150_24 |
| 80 | P1-25: Impact of isolated calf deep vein thrombosis on clinical manifestation
10.1111/resp.14150_25 |
| 80 | P1-26: Cytokines secreted by PC9-MET and PC9 cells may worsen COVID-19
10.1111/resp.14150_26 |
| 81 | P1-27: The impact of electronic smoking systems on the bronchopulmonary system
10.1111/resp.14150_27 |
| 81 | P1-28: Erector spinae muscle radiographic density predicts survival after lung transplantation
10.1111/resp.14150_28 |
| 81 | P1-29: Clinical characteristics of preserved ratio impaired spirometry in Japan
10.1111/resp.14150_29 |
| 82 | P1-30: Sleep architecture of short sleep time in patients with obstructive sleep apnea: A retrospective single-facility research
10.1111/resp.14150_30 |
| 82 | P1-31: A randomized crossover exploratory study comparing the effect of an auto-demand oxygen delivery system with that of a normal demand oxygen delivery system
10.1111/resp.14150_31 |
| 83 | P1-32: A case report of a fatal pulmonary tumour emboli
10.1111/resp.14150_32 |
| 83 | P1-33: Careful history taking detects underlying disorders of initially unknown causes of aspiration pneumonia
10.1111/resp.14150_33 |
| 84 | P1-34: Passive microwave radiometry as an early screening diagnostic of pneumonia due to coronavirus infection 2019 lung complications in Kyrgyzstan
10.1111/resp.14150_34 |
| 85 | P1-35: A case of chronic type II respiratory failure due to Bethlem myopathy
10.1111/resp.14150_35 |
| 85 | P1-36: Multicenter study elucidating factors associated with sequelae of discharged COVID-19 patients in Japan
10.1111/resp.14150_36 |
| 86 | P1-37: Correlation of the effectiveness of hemodialysis and pleuropulmonary findings by thoracic ultrasound in patients with chronic kidney disease
10.1111/resp.14150_37 |
| 87 | P1-38: Impact of cisplatin and pemetrexed on VEGFR-1 on inducing anticancer effects in KRAS-dependent A549 cells
10.1111/resp.14150_38 |
| 87 | P1-39: Paclitaxel induces growth inhibition in gefitinib-resistant PC9-MET cells by downregulating MDM2 and activating p53
10.1111/resp.14150_39 |
| 87 | P1-40: Pig bronchus: A rare tracheobronchial anomaly causing lung collapse and recurrent pneumonia
10.1111/resp.14150_40 |
| 88 | P1-41: Impact of respiratory failure service on management of acute hypercapnic respiratory failure in Liverpool Hospital
10.1111/resp.14150_41 |
| 88 | P1-42: Use of indwelling pleural catheters as a palliative care intervention for malignant pleural effusions at Queen Elizabeth Hospital, Woolwich
10.1111/resp.14150_42 |
| 89 | P1-43: Inter-hospital collaboration of sleep services programs between Kowloon Hospital (KH) and Queen Elizabeth Hospital (QEH)
10.1111/resp.14150_43 |
| 89 | P1-44: Pulmonary amyloidosis due to IgG lambda myeloma – An unusual presentation
10.1111/resp.14150_44 |
| 90 | P1-45: Resolving persistent bilateral pneumothorax without performing video-assisted thoracoscopic surgery (VATS): A case report
10.1111/resp.14150_45 |
| 90 | P1-46: A case of bronchial obstruction due to pulmonary hypertension
10.1111/resp.14150_46 |
| 91 | P1-47: Clinical characteristics of severe COVID19 patients
10.1111/resp.14150_47 |
| 91 | P1-48: Metabolism of traditional Chinese medicine in the treatment of allergic rhinitis
10.1111/resp.14150_48 |
| 92 | P1-49: General practitioner and specialists perceptions of clinical pathways for management of chronic breathlessness in primary care
10.1111/resp.14150_49 |
| 92 | P1-50: Radiological findings of EVALI: A systematic review
10.1111/resp.14150_50 |
| 93 | P1-51: Status of palliative care in respiratory disease before and after COVID-19 outbreak
10.1111/resp.14150_51 |
| 93 | P1-52: Successful case of non-HIV pneumocystis pneumonia treated with extracorporeal membrane oxygenation (ECMO)
10.1111/resp.14150_52 |
| 94 | P1-53: The combination of sarcoid lymphadenopathy and cystic formation of the mediastinum: Ways to optimize radiation diagnostics
10.1111/resp.14150_53 |
| 94 | P1-54: Paclitaxel impedes g1 phase progression in gefitinib-resistant non-small-cell lung cancer
10.1111/resp.14150_54 |
| 94 | P1-55: Pulmonary function after nintedanib treatment in post-COVID-19 pulmonary fibrosis
10.1111/resp.14150_55 |
| 95 | P1-56: A case of pulmonary alveolar proteinosis with severe respiratory failure improved by segmental lung lavage with fiberoptic bronchoscopy under general anesthesia
10.1111/resp.14150_56 |
| 95 | P1-57: Kartagener's syndrome: A case report of a lady with poorly resolving asthma
10.1111/resp.14150_57 |
| 96 | P1-58: Successful treatment of complex multiloculated chylothorax with single low dose intrapleural alteplase
10.1111/resp.14150_58 |
| 97 | P1-59: Co-relation of age, sex, diffusion and volume defects with HRCT chest scoring in post COVID patients with exertional breathlessness in Bangladesh
10.1111/resp.14150_59 |
| 98 | P1-60: An innocent vascular ring in an adult asthmatic patient; incidental balanced type double aortic arch
10.1111/resp.14150_60 |
| 98 | P1-61: Research of respiratory sequelae in COVID 19 patients at 3 months
10.1111/resp.14150_61 |
| 98 | P1-62: Elderly sarcoidosis in Japan
10.1111/resp.14150_62 |
| 99 | P1-63: Respiratory responses during two minutes walking in late-stage elderly people
10.1111/resp.14150_63 |
| 99 | P1-64: A case of misdiagnosis of pulmonary hamartoma
10.1111/resp.14150_64 |
| 100 | P1-65: Two cases of Castleman's disease with lung lesions controlled by tocilizumab
10.1111/resp.14150_65 |
| 100 | P1-66: Metastatic pulmonary calcification mimicking miliary pulmonary tuberculosis: A case report
10.1111/resp.14150_66 |
| 100 | P1-67: Silicosis, tuberculosis and dermatomyositis - Are they connected?
10.1111/resp.14150_67 |
| 101 | P1-68: Association between smoking and physical fitness measured using 6-minutes walking test in nonstaff employee University of Indonesia, Depok: A cross-sectional study
10.1111/resp.14150_68 |
| 101 | P1-69: Acquired esophago-airway fistula in adults: A case report
10.1111/resp.14150_69 |
| 102 | P1-70: Yokukansan and in-hospital mortality in patients with pneumonia
10.1111/resp.14150_70 |
| 102 | P1-71: Breath-actuated inhalation therapy: Survey of physicians' perception (INTROSPECT) in Nepal
10.1111/resp.14150_71 |
| 102 | P1-72: A case of lung intravascular large B cell lymphoma developed with acute respiratory failure: Usefulness of corticosteroid rescue prior to define diagnosis
10.1111/resp.14150_72 |
| 103 | P1-73: Dry needling and orthopnoea: A case of bilateral, atraumatic phrenic nerve demyelination
10.1111/resp.14150_73 |
| 103 | P1-74: COVID-19 in renal transplant recipients in a resource poor setting: A case series
10.1111/resp.14150_74 |
| 104 | P1-75: Shrinking lung treatment responding to cyclophosphamide pulses - A case report
10.1111/resp.14150_75 |
| 104 | P1-76: Rare endobronchial squamous papilloma causing recurrent pneumonia
10.1111/resp.14150_76 |
| 105 | P1-77: Long-COVID syndrome associated with COVID-19 pneumonia
10.1111/resp.14150_77 |
| 105 | P1-78: Descriptive analysis of patients attending an outpatient post COVID-19 clinic in a tertiary care hospital in Sri Lanka
10.1111/resp.14150_78 |
| 106 | P1-79: Diaphragm dysfunction developed after COVID-19 infection without pneumonia
10.1111/resp.14150_79 |
| 106 | P1-80: Clinical analysis of lung bullas with spontaneous regression after abscess
10.1111/resp.14150_80 |
| 106 | P1-81: Malignant pleural effusion in a newly-diagnosed multiple myeloma patient
10.1111/resp.14150_81 |
| 107 | P1-82: Successful treatment of bilateral diaphragmatic paralysis from HIV associated axonal polyneuropathy with bilevel positive airway pressure - A case report
10.1111/resp.14150_82 |
| 107 | P1-83: A case report of primi 30 weeks of pregnancy with COVID-19 pneumonia with dengue fever
10.1111/resp.14150_83 |
| 108 | P1-84: Airway management training for nursing staff of TB and Chest Unit, Grantham Hospital
10.1111/resp.14150_84 |
| 108 | P1-85: Knowledge, awareness and practices of nurses and respiratory therapists regarding administering inhaler gadget education to admitted patients prescribed with an inhaler device
10.1111/resp.14150_85 |
| 108 | P1-86: Prone positioning treatment for COVID-19 ARDS patients with pneumomediastinum and subcutaneous emphysema during treatment of mechanical ventilation.: A two cases report
10.1111/resp.14150_86 |
| 109 | P1-87: Dyspnea eight years post craniopharyngioma resection
10.1111/resp.14150_87 |
| 109 | P1-88: Persistent bilateral unprovoked pulmonary embolism - A case of chronic thromboembolic pulmonary hypertension in a young lady with seronegative antiphospholipid syndrome
10.1111/resp.14150_88 |
| 110 | P1-89: Postural herniation of a skeletal muscle hemangioma through intercostal space
10.1111/resp.14150_89 |
| 110 | P1-90: Increased risk of suicide attempt among patients receiving blood transfusion: The good, the bad and the ugly
10.1111/resp.14150_90 |
| 110 | P1-91: Two cases of polypharmacy-Associated aspiration pneumonia: A possible role of aging lung
10.1111/resp.14150_91 |
| 111 | P1-92: Para-spinal neurilemmoma with an atypical thoracic discomfort-An undescribed entity
10.1111/resp.14150_92 |
| 111 | P1-93: A case of lung mass with bifurcation that was difficult to differentiate from lung cancer
10.1111/resp.14150_93 |
| 111 | P1-94: The challenges of patients that with home using long term oxygen therapy under coronavirus pandemic
10.1111/resp.14150_94 |
| 112 | P1-95: It runs in the family: case series of severe and critical COVID-19 in three family members
10.1111/resp.14150_95 |
| Cell and Molecular Biology | |
| 112 | P2-1: Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity
10.1111/resp.14150_96 |
| 113 | P2-2: Mesenchymal stem cells cultured in serum-free medium suppress murine bleomycin-induced pulmonary fibrosis by enhancing regulatory T cell induction
10.1111/resp.14150_98 |
| 113 | P2-3: Isolation and characterization of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis
10.1111/resp.14150_99 |
| 114 | P2-4: miR103a-3p in extracellular vesicles from FcεRI-aggregated human mast cells enhances IL-5 production by group 2 innate lymphoid cells
10.1111/resp.14150_100 |
| 114 | P2-5: TGF-Β-induced epithelial-mesenchymal transition and tumor-promoting effects in CMT64 cells are reflected in the transcriptomic signature of human lung adenocarcinoma
10.1111/resp.14150_101 |
| 115 | P2-6: Folliculin haploinsufficiency causes cellular dysfunction of pleural mesothelial cells
10.1111/resp.14150_102 |
| 115 | P2-7: Alleviation of mouse LPS-induced lung injury by CD26/DPP4 deficiency
10.1111/resp.14150_103 |
| 115 | P2-8: Exosomal micro RNA-146a derived from human lung fibroblasts could modulate cyclooxygenase 2 gene expression
10.1111/resp.14150_104 |
| 116 | P2-9: Soluble ST2 enhances IL-33–induced neutrophilic airway inflammation: A potential mechanism of neutrophilic asthma
10.1111/resp.14150_105 |
| 116 | P2-10: Role of MAP3K19 in allergic airway inflammation of asthma
10.1111/resp.14150_106 |
| 117 | P2-11: Application of conditional reprogramming culture to analyze Japanese primary ciliary dyskinesia
10.1111/resp.14150_107 |
| 117 | P2-12: Drug resistance is associated with upregulation of metabolic enzymes in malignant pleural mesothelioma
10.1111/resp.14150_108 |
| 118 | P2-13: Cold-shock proteins are upregulated in asthma patients with cold airway hyperresponsiveness and provoke increase in MUC5AC expression under cooling
10.1111/resp.14150_109 |
| 118 | P2-14: Oxytocin receptor is a promising therapeutic target of malignant mesothelioma
10.1111/resp.14150_110 |
| 118 | P2-15: An HTERT/CDK4-immortalized normal human bronchial epithelial cell line is highly resistant to mutant KRAS-induced senescence
10.1111/resp.14150_111 |
| 119 | P2-16: Inflammatory cytokine derived from inflammasome in tumor-associated macrophages enhances malignant potential of malignant pleural mesothelioma
10.1111/resp.14150_112 |
| 120 | P2-17: Nintedanib inhibits epithelial-mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF-Β/Smad pathway
10.1111/resp.14150_113 |
| 120 | P2-18: Establishment of acquired pemetrexed-resistant MPM cell lines and evaluation of an IGF-1R inhibitor picropodophyllin for MPM treatment
10.1111/resp.14150_114 |
| 120 | P2-19: The effect of X-ray irradiation and glucocorticoid on the barrier function in rat alveolar epithelial cells
10.1111/resp.14150_115 |
| 121 | P2-20: Propylene glycol and glycerol, components of E-cigarettes and heated tobacco products, damage epithelial cells in human airways
10.1111/resp.14150_116 |
| 121 | P2-21: PI3-kinase delta differentially regulates antiviral interferon-induced expression of programmed death 1 ligand 1 and ligand 2 in human primary bronchial epithelial cells
10.1111/resp.14150_117 |
| 122 | P2-22: Imaging changes and immune-checkpoint expression on T cells in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis
10.1111/resp.14150_118 |
| 122 | P2-23: Hypercapnia accelerates adipogenesis: A novel role of high CO2 in exacerbating obesity
10.1111/resp.14150_119 |
| 122 | P2-24: Ways to tackle the highly transmissible delta virus
10.1111/resp.14150_120 |
| 123 | P2-25: Iron mediates cigarette smoke-induced ACE2 expression in bronchial epithelial cells
10.1111/resp.14150_121 |
| 123 | P2-26: Effect of lycopene on lung aging and oxidative stress in senescence-accelerated mouse P1 strain
10.1111/resp.14150_122 |
| 123 | P2-27: Identification of inhibitors targeting heat shock protein 47 for the development of anti-fibrotic therapeutics
10.1111/resp.14150_123 |
| 124 | P2-28: Targeting emt by suppression of LSD1 in malignant pleural mesothelioma
10.1111/resp.14150_124 |
| 124 | P2-29: Short-term intermittent cigarette smoke exposure enhances the stemness of alveolar type 2 cells through activation of fatty acid oxidation
10.1111/resp.14150_125 |
| 124 | P2-30: Resolvin E3 attenuates profibrotic factor production via its action on macrophages
10.1111/resp.14150_126 |
| 125 | P2-31: Expression of programmed death ligand 1 (PD-L1) in thymoma
10.1111/resp.14150_127 |
| 125 | P2-32: Oral bacterial neuraminidase enhances influenza virus infections
10.1111/resp.14150_128 |
| 126 | P2-33: Blocking MMP-12-modulated epithelial-mesenchymal transition by repurposing penfluridol retsrains lung adenocarcinoma metastasis via UPA/UPAR/TGF-Β/AKT pathway
10.1111/resp.14150_129 |
| 126 | P2-34: Differential gene expression in airway epithelial cells after preterm birth
10.1111/resp.14150_130 |
| 126 | P2-35: Identification of prognostic and therapeutic biomarker of tumor immune-micro-environment infiltrating lymphocytes INOF malignant pleural mesothelioma: A spatial analysis in Asian population
10.1111/resp.14150_131 |
| 127 | P2-36: Activation of G protein-coupled estrogen receptor (GPER) regulates ILC2
10.1111/resp.14150_132 |
| 127 | P2-37: The mechanism of cigarette smoke-induced mitchondrial DNA release in pulmonary epithelial cell
10.1111/resp.14150_133 |
| 128 | P2-38: Examination of microRNAs in serum exosomes in interstitial pneumonia
10.1111/resp.14150_134 |
| 128 | P2-39: Assessment of inter-lobe biological diversity in the lung by DNA methylation profiles in autopsy cases
10.1111/resp.14150_135 |
| 128 | P2-40: Expression of the SARS-CoV-2 receptor ACE2 and proinflammatory cytokines induced by the periodontopathic bacterium Fusobacterium nucleatum in human respiratory epithelial cells
10.1111/resp.14150_136 |
| 129 | P2-41: Porphyromonas gingivalis gingipains potentially affects MUC5AC gene expression and protein levels in respiratory epithelial cells
10.1111/resp.14150_137 |
| 129 | P2-42: Effects of protease-activated receptor antagonist on steroid insensitive airway inflammation induced by LPS in mice
10.1111/resp.14150_138 |
| 130 | P2-43: Effect of oxidative stress on the production of DSDNA-induced interferon in airway epithelial cells
10.1111/resp.14150_139 |
| 130 | P2-44: Exposure to Porphyromonas gingivalis induces production of proinflammatory cytokine via TLR2 from human respiratory epithelial cells
10.1111/resp.14150_140 |
| 130 | P2-45: Porphyromonas gingivalis enhances pneumococcal adhesion to human alveolar epithelial cells by increasing expression of host platelet-activating factor receptor
10.1111/resp.14150_141 |
| 131 | P2-46: Effect of high fat diet on the severity and repair of lung fibrosis in mice
10.1111/resp.14150_142 |
| 131 | P2-47: Double stranded RNA induces vulnerability of airway epithelial barrier integrity by influencing airway basal cells
10.1111/resp.14150_143 |
| 132 | P2-48: Correlation between MGAT4a and MGAT5 expression and poorer outcome in advanced lung adenocarcinoma
10.1111/resp.14150_144 |
| 132 | P2-49: The Japanese herbal medicine Hochuekkito (TJ-41) reduces lung inflammation in COPD exacerbation mouse model
10.1111/resp.14150_145 |
| 132 | P2-50: TLR3 signaling induces IFITM1 expression via IFN-B and ISG56 in cultured BEAS-2B bronchial epithelial cells
10.1111/resp.14150_146 |
| 133 | P2-51: Action of Panton-Valentine leukocidin on rabbit alveolar macrophages
10.1111/resp.14150_147 |
| 133 | P2-52: Rosa Roxburghii Tratt compounds with anti-lung cancer potential
10.1111/resp.14150_148 |
| 133 | P2-53: Quercetin attenuated the inflammatory response in LPS-induced ALI mouse model
10.1111/resp.14150_149 |
| 134 | P2-54: Lack of TRPA1-mediated effect in cigarette smoke-induced inhibition of phagocytosis
10.1111/resp.14150_150 |
| 134 | P2-55: Cigarette smoke reduces CXCL10 production by macrophages via TRPA1-dependent mechanism
10.1111/resp.14150_151 |
| 135 | P2-56: Metal-dependent oxidative alveolar type ii cell injury by fine indoor PM
10.1111/resp.14150_152 |
| 135 | P2-57: The periodontopathic bacterium Fusobacterium nucleatum induced proinflammatory cytokine production by human respiratory epithelial cell lines and in the lower respiratory organs in mice
10.1111/resp.14150_153 |
| 135 | P2-58: Effects of food nutritional components on lung cancer cell lines
10.1111/resp.14150_154 |
| 136 | P2-59: Medicinal importance of asiaticoside in the medicine for the treatment of for pancreatobiliary disorders
10.1111/resp.14150_155 |
| Clinical Allergy and Immunology | |
| 136 | P3-1: Differential model of the deep convolutional neural network between sarcoidosis and lymphoma in 18F-FDG-PET/CT
10.1111/resp.14150_157 |
| 137 | P3-2: Impact of air pollutant of polycyclic aromatic hydrocarbons (PAHS) on the yearly decline of pulmonary function in asthmatics sensitized to house dust mite (HDM)
10.1111/resp.14150_158 |
| 137 | P3-3: Tiotropium bromide attenuates ILC2-derived type-2 cytokine production by suppressing IL-4 production from basophils
10.1111/resp.14150_159 |
| 138 | P3-4: THE TL1A/DR3 axis in the presence of TSLP induces steroid resistance of ILC2
10.1111/resp.14150_160 |
| 138 | P3-5: Serum periostin levels and periostin immunostaining were useful in the evaluation of eosinophilic granulomatosis with polyangiitis patients
10.1111/resp.14150_161 |
| 138 | P3-6: A clinical analysis of PAP (pulmonary alveolar proteinosis) s diagnosed with difficulty in the COVID-19 pandemic
10.1111/resp.14150_162 |
| 139 | P3-7: Mepolizumab may not induct long term remission in patients with eosinophilic granulomatosis with polyangiitis with high relapse rates
10.1111/resp.14150_163 |
| 139 | P3-8: Clinical application of serum and sputum YKL-40 in asthma, ACO and COPD
10.1111/resp.14150_164 |
| 139 | P3-9: Allergy in IgG4-related disease
10.1111/resp.14150_165 |
| 140 | P3-10: Metabolism profiling of allergic rhinitis in children and adult
10.1111/resp.14150_166 |
| 140 | P3-11: A novel mechanism for tweak induces the production of TSLP, RANTES, MIP-1Α and TARC in BEAS-2B human bronchial epithelial cells during epithelial-mesenchymal transition
10.1111/resp.14150_167 |
| 141 | P3-12: A case of unilateral eosinophilic pneumonia associated with primary biliary cholangitis (PBC)
10.1111/resp.14150_168 |
| 141 | P3-13: IL-17A acutely modulates airway smooth muscle contractility by PKC-alpha-mediated RhoA activation
10.1111/resp.14150_169 |
| 141 | P3-14: Changing anti-nuclear antibody profile in a patient with eosinophilic granulomatosis with polyangiitis: A case report
10.1111/resp.14150_170 |
| 142 | P3-15: Oral mite anaphylaxis after ingestion of Korean pancake
10.1111/resp.14150_171 |
| 142 | P3-16: Effects of eosinophils on patients with allergic rhinitis
10.1111/resp.14150_172 |
| 142 | P3-17: Cases of bronchial asthma with eosinophil sinusitis and atopic dermatitis for which dupilumab was effective
10.1111/resp.14150_173 |
| 143 | P3-18: IL-17A with TNF-α synergistically enhances mouse airway smooth muscle contraction
10.1111/resp.14150_174 |
| Environmental and Occupational Health and Epidemiology | |
| 143 | P4-1: Withdrawn
10.1111/resp.14150_176 |
| 143 | P4-2: Mite allergen avoidance decreases allergic symptoms in children in Ishinomaki City after natural disasters
10.1111/resp.14150_177 |
| 143 | P4-3: What are the factors contributing to decreased physical activity in outpatients with respiratory diseases?
10.1111/resp.14150_178 |
| 144 | P4-4: Role of the thiol-disulphide system in the protection of alveolar macrophages against exposure to suspended particle matter of the atmospheric surface layer
10.1111/resp.14150_179 |
| 144 | P4-5: Withdrawn
10.1111/resp.14150_180 |
| 144 | P4-6: Pleural fluid cytokeratin 19 fragment and other factors well predict diffuse pleural thickening among patients with benign asbestos pleural effusions
10.1111/resp.14150_181 |
| 145 | P4-7: Associations between long-term exposure to PM10 and NO2 and serum metabolite concentration in CODA cohort
10.1111/resp.14150_182 |
| 145 | P4-8: Toxicity of two different biodiesel exhausts in primary human airway epithelial cells grown at air-liquid interface
10.1111/resp.14150_183 |
| 146 | P4-9: Withdrawn
10.1111/resp.14150_184 |
| 146 | P4-10: Burnout among healthcare workers during COVID-19 pandemic in Aceh, Indonesia
10.1111/resp.14150_185 |
| 146 | P4-11: Results of questionnaire survey on the use of new type tobacco (heated or electronic cigarettes) in households with minors
10.1111/resp.14150_186 |
| 146 | P4-12: Dynamics and regional gradients of respiratory diseases on the territory of the Far Eastern Federal District of Russia
10.1111/resp.14150_187 |
| 147 | P4-13: Assessment of the impact of atmospheric air microsuspensions on the respiratory function of patients with chronic obstructive pulmonary disease
10.1111/resp.14150_188 |
| 147 | P4-14: Hydrofluorocarbons pneumonitis as a complication of inhalation injury following air-conditioning repairs
10.1111/resp.14150_189 |
| 148 | P4-15: A clinical research of heated tobacco products users in our smoking cessation clinic
10.1111/resp.14150_190 |
| 148 | P4-16: Swallowing dysfunction in patients with chronic respiratory disease
10.1111/resp.14150_191 |
| 149 | P4-17: Don't bring home that bacon: A report of two simultaneous cases of Streptococcus suis meningitis
10.1111/resp.14150_192 |
| 149 | P4-18: Comparative analysis of the incidence of respiratory diseases among urban and rural population
10.1111/resp.14150_193 |
| 150 | P4-19: Comparison of expiratory carbon monoxide level in white and clove cigarette among college students smokers
10.1111/resp.14150_194 |
| 150 | P4-20: Correlation between smoking behavior and level of nicotine dependence in actively smoking college students
10.1111/resp.14150_195 |
| 150 | P4-21: Fitness level studies using 6-minute walking test method and its relationship to the type of work on non staff employees of Universitas Indonesia Depok
10.1111/resp.14150_196 |
| 151 | P4-22: The effect and safety of ultraviolet germicidal irradiation on reusing N95 filtering facepiece respirators at weekly intervals
10.1111/resp.14150_197 |
| 151 | P4-23: A case report of bronchial anthracofibrosis – A Sri Lankan experience
10.1111/resp.14150_198 |
| 152 | P4-24: Respiratory symptoms and lung function among active smokers in Indonesian college students
10.1111/resp.14150_199 |
| 152 | P4-25: The dynamics of the quality of life of healthy people amid the COVID-19 pandemic when soy and pumpkin products are included in the diet
10.1111/resp.14150_200 |
| 153 | P4-26: Withdrawn
10.1111/resp.14150_201 |
| 153 | P4-27: Correlation between smoking habit and factors that determines smoking habit in male college students in Depok
10.1111/resp.14150_202 |
| 153 | P4-28: Case series: High flow nasal cannula in carbon monoxide intoxication
10.1111/resp.14150_203 |
| 153 | P4-29: Association between physical activity and physical fitness of the janitors in the Universitas Indonesia, Depok
10.1111/resp.14150_204 |
| 154 | P4-30: The relationship of nutritional status of nonstaff UI Depok employees with fitness level using the 6 minute walking test method
10.1111/resp.14150_205 |
| 154 | P4-31: Therapeutic benefit and pharmacological potential of rhamnazin: Biological role in the medicine through scientific data analysis
10.1111/resp.14150_206 |
| Respiratory Infections (non-tuberculous) | |
| 154 | P5-1: Factors associated with the development of bacterial pneumonia related to seasonal influenza virus infection: A study using a large-scale health insurance claim database
10.1111/resp.14150_208 |
| 155 | P5-2: Intrathoracic vacuum-assisted closure therapy for the management of acute lung abscess
10.1111/resp.14150_209 |
| 155 | P5-3: Efficacy and safety of first-line therapy for pulmonary nocardiosis; trimethoprim/sulfamethoxazole versus alternative antibiotics
10.1111/resp.14150_210 |
| 156 | P5-4: Withdrawn
10.1111/resp.14150_211 |
| 156 | P5-5: Impaired functional activities related to prolonged hospitalization among the patients of community acquired pneumonia
10.1111/resp.14150_212 |
| 156 | P5-6: A convenient risk prediction score for COVID-19 in determining whether hospitalization should be recommended: Kanagawa admission priority assessment score (KAPAS)
10.1111/resp.14150_213 |
| 157 | P5-7: Phagocytotic analysis of alveolar macrophage phenotypes in patients with Mycobacterium avium complex lung disease
10.1111/resp.14150_214 |
| 157 | P5-8: Risk factors for mortality of COVID-19 confirmed cases admitted at lung center of the Philippines
10.1111/resp.14150_215 |
| 158 | P5-9: Microbiologic pattern and clinical outcome of hospital acquired pneumonia in a general ward: Korean hap registry analysis
10.1111/resp.14150_216 |
| 159 | P5-10: The influence of rifampicin dosage in radiological outcomes of Mycobacterium kansasii lung disease
10.1111/resp.14150_217 |
| 159 | P5-11: Vaccine-induced immune thrombotic thrombocytopenia (VITT) after ChAdOx1 nCoV-19 vaccination
10.1111/resp.14150_218 |
| 160 | P5-12: Clinical characteristics distinguish between acute cardiogenic pulmonary edema and community-associated pneumonia in the elderly patients
10.1111/resp.14150_219 |
| 160 | P5-13: COVID-19 mobile test unit (COMBAT): A novel pharyngeal sampling platform for COVID-19 testing in Malaysia
10.1111/resp.14150_220 |
| 161 | P5-14: An age-matched comparison between COVID-19 pneumonia and pneumococcal pneumonia cases
10.1111/resp.14150_221 |
| 161 | P5-15: A case of recurred exacerbations and remissions of COVID-19 pneumonia in a patient with b-cell lymphoma undergoing chemotherapy
10.1111/resp.14150_222 |
| 162 | P5-16: Lung transplantation cases with nontuberculous mycobacteriosis
10.1111/resp.14150_223 |
| 162 | P5-17: The first and second wave of COVID 19 in rural India: A comparison of inflammatory markers with severity of pneumonia
10.1111/resp.14150_224 |
| 163 | P5-18: Risk factors associated with methicillin-resistant Staphylococcus aureus pneumonia among adult patients at St. Luke's Medical Center, Philippines
10.1111/resp.14150_225 |
| 163 | P5-19: Spontaneous pneumothorax in Indonesian COVID-19 patients: A retrospective case series
10.1111/resp.14150_226 |
| 163 | P5-20: The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society
10.1111/resp.14150_227 |
| 164 | P5-21: Serum ferritin levels: A cost-effective marker for severity of pneumonia in patients with COVID 19
10.1111/resp.14150_228 |
| 164 | P5-22: Epidemiology and outcomes of non-tuberculous mycobacterial pulmonary disease in Auckland, New Zealand
10.1111/resp.14150_229 |
| 165 | P5-23: Neurological complications of patients with COVID-19
10.1111/resp.14150_230 |
| 166 | P5-24: Severity and clinical outcome of SARS-CoV-2 infected patients following COVID vaccination – An observational study in Bangladesh
10.1111/resp.14150_231 |
| 166 | P5-25: Spontaneous development of pneumocystis pneumonia in mice lacking death ligand-induced apoptosis and necroptosis
10.1111/resp.14150_232 |
| 167 | P5-26: Validity of PIRO-score as an assessment tool for mortality risk of COVID-19 pneumonia in World Citi Medical Center. A retrospective observational cohort study
10.1111/resp.14150_233 |
| 167 | P5-27: Evaluation of serum interferon lambda 3 in hospitalized COVID-19 patients as a biomarker to predict the severity
10.1111/resp.14150_234 |
| 168 | P5-28: Correlation of serum interleukin-6 level and COVID-19 severity on hospital admission and survival
10.1111/resp.14150_235 |
| 168 | P5-29: Fungal hydro-pneumothoraces! A series of patients presenting with hydro-pneumothoraces secondary to invasive fungal infection and a review of literature regarding the same
10.1111/resp.14150_236 |
| 168 | P5-30: Risk factors for hospitalization in patients with mild SARS-CoV-2 infection (COVID-19) during residential or home care
10.1111/resp.14150_237 |
| 169 | P5-31: High prevalence of silent hypoxia among patients with COVID-19 warrants screening for oxyhemoglobin desaturation among patients with fever, cough or dyspnea
10.1111/resp.14150_238 |
| 169 | P5-32: Investigation of exacerbation factors in patients with coronavirus disease 2019
10.1111/resp.14150_239 |
| 170 | P5-33: Impacts of the COVID-19 pandemic on hospitalizations for pneumonia in Brazil
10.1111/resp.14150_240 |
| 170 | P5-34: Long-haul COVID-19 among University of Santo Tomas hospital-health care workers following hospitalization for COVID-19 pneumonia
10.1111/resp.14150_241 |
| 170 | P5-35: Successful treatment of disseminated nontuberculous infection with Mycobacterium genavense mimicking malignancy in a patient with anti–interferon-gamma (IFN-Γ) autoantibodies
10.1111/resp.14150_242 |
| 171 | P5-36: Association of C-reactive protein (CRP), serum ferritin, and patient outcome in COVID-19 patients in tertiary referral hospital
10.1111/resp.14150_243 |
| 171 | P5-37: Community-acquired respiratory virus cases mimic COVID-19 on lung computed tomography
10.1111/resp.14150_244 |
| 171 | P5-38: Effects of adjunctive corticosteroids on Pneumocystis pneumonia in non-HIV-infected patients at five facilities in Nagano Prefecture
10.1111/resp.14150_245 |
| 172 | P5-39: Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after commencing treatment
10.1111/resp.14150_246 |
| 172 | P5-40: An autopsy case of COVID-19 with disseminated mucormycosis
10.1111/resp.14150_247 |
| 173 | P5-41: Rapid and simultaneous identification of multiple mutations by the NovaplexTM SARS-CoV-2 variants assay kits
10.1111/resp.14150_248 |
| 173 | P5-42: Assessment of outcome and risk categorization of COVID-19 exposed healthcare workers using a risk assessment tool in a Tertiary Care Hospital, Sri Lanka
10.1111/resp.14150_249 |
| 173 | P5-43: A case of hyperpyrexia of hypothalamic origin associated with severe COVID-19 pneumonia in pregnancy
10.1111/resp.14150_250 |
| 174 | P5-44: Pulmonary nontuberculous mycobacterial infection in patients with rheumatoid arthritis on biological therapy
10.1111/resp.14150_251 |
| 174 | P5-45: Osteoporosis in nontuberculous mycobacterial pulmonary disease
10.1111/resp.14150_252 |
| 175 | P5-46: Myocardial injury association with severity of disease in hospitalized COVID-19 patients
10.1111/resp.14150_253 |
| 175 | P5-47: Safety and efficacy of remdesivir, baricitinib and high-dose steroid combination therapy in patients hospitalized with COVID-19
10.1111/resp.14150_254 |
| 176 | P5-48: Shrot versus long antibiotic course for pleural infection management: A randomised trial
10.1111/resp.14150_255 |
| 176 | P5-49: Withdrawn
10.1111/resp.14150_256 |
| 176 | P5-50: Withdrawn
10.1111/resp.14150_257 |
| 176 | P5-51: Organizing pneumonia post COVID-19: Outcomes of treatment with corticosteroids in the outpatient setting
10.1111/resp.14150_258 |
| 176 | P5-52: Evaluation of the luminex xTAG respiratory viral panel fast v2 assay for rapid diagnosis of respiratory viral infections
10.1111/resp.14150_259 |
| 177 | P5-53: Early initiation of steroid therapy is a risk factor of treatment failure in patients with COVID-19
10.1111/resp.14150_260 |
| 177 | P5-54: Guillain-Barre syndrome-acute motor axonal neuropathy as neurologic sequela in a COVID-19 critically-ill patient: A case report
10.1111/resp.14150_261 |
| 178 | P5-55: What kind of disease has developed in a teenager against the background of a new coronavirus infection? Is it Kawasaki's or Reye's syndrome?
10.1111/resp.14150_262 |
| 178 | P5-56: Predictive model for the development of critical coronavirus disease 2019 in Japan
10.1111/resp.14150_263 |
| 179 | P5-57: Comparison of chest HRCT findings between COVID-19 pneumonia and anti-MDA5 antibody-positive interstitial pneumonia by computer-based quantitative CT image analysis
10.1111/resp.14150_264 |
| 180 | P5-58: Efficacy of concurrent administration of tocilizumab with corticosteroids for patients with COVID-19
10.1111/resp.14150_265 |
| 180 | P5-59: Comparative analysis of the course of post-COVID-19 syndrome in individuals of different age groups
10.1111/resp.14150_266 |
| 180 | P5-60: Clinical and radiological features of COVID-19 in pregnant women: A case-control study
10.1111/resp.14150_267 |
| 181 | P5-61: Online team-based learning: A novel pedagogical approach for undergraduate MBBS students
10.1111/resp.14150_268 |
| 181 | P5-62: Evaluation of lung cell populations in severe COVID-19 pneumonia
10.1111/resp.14150_269 |
| 181 | P5-63: Effect of hyperbaric oxygen therapy among COVID19 patients: A meta-analysis
10.1111/resp.14150_270 |
| 182 | P5-64: Therapeutic effectiveness & safety of favipiravir in COVID-19 patients with risk factors for mortality: Clinical practice experience from India
10.1111/resp.14150_271 |
| 182 | P5-65: Association between clinical, microbiologic profile, and outcomes of patients with ventilator associated pneumonia admitted in the critical care unit in San Juan de Dios Hospital
10.1111/resp.14150_272 |
| 183 | P5-66: Withdrawn
10.1111/resp.14150_273 |
| 183 | P5-67: Predictors of mortality in severe COVID-19 pneumonia: An interim analysis from a single Tertiary Care Centre in Central Sri Lanka
10.1111/resp.14150_274 |
| 183 | P5-68: The use of an institutionalized respiratory protocol as a decision-making tool improved outcomes among severe and critically-ill COVID-19 patients in Perpetual Succour Hospital
10.1111/resp.14150_275 |
| 184 | P5-69: Patterns of chronic pulmonary aspergillosis in Sri Lanka
10.1111/resp.14150_276 |
| 184 | P5-70: Effectiveness of favipiravir in COVID-19 patients with multiple (≥2) or less (<2) comorbidities: A real word experience from India
10.1111/resp.14150_277 |
| 184 | P5-71: Rapidly progressive honeycombing in a spontaneously breathing patient with COVID-19 pneumonia
10.1111/resp.14150_278 |
| 185 | P5-72: Lipid involvements on inflammatory changes and clinical outcomes in patients with COVID-19
10.1111/resp.14150_279 |
| 186 | P5-73: Clinical characteristics of pulmonary melioidosis diagnosed at respiratory Department of the Tertiary Hospital in Southern Vietnam
10.1111/resp.14150_280 |
| 186 | P5-74: Serial changes in clinical characteristics of COVID-19 infected patients
10.1111/resp.14150_281 |
| 187 | P5-75: Risk factors for pneumonia in nursing home residents
10.1111/resp.14150_282 |
| 187 | P5-76: Prolonged viral clearance in COVID-19 patients treated with tocilizumab
10.1111/resp.14150_283 |
| 187 | P5-77: Prognostic factors associated with death and progressiveness of COVID-19 disease at Sanglah Hospital, Denpasar
10.1111/resp.14150_284 |
| 188 | P5-78: Pulmonary nocardiosis with osteolytic lesions mimicking lung cancer
10.1111/resp.14150_285 |
| 188 | P5-79: Clinical comparison of the first wave and the later waves in COVID-19 patients with pneumonia
10.1111/resp.14150_286 |
| 189 | P5-80: A case report of pneumothorax associated with COVID-19 pneumoniae
10.1111/resp.14150_287 |
| 189 | P5-81: Correlation of serum ferritin level with disease severity of COVID-19 at Arifin Achmad General Hospital Riau Province
10.1111/resp.14150_288 |
| 189 | P5-82: The correlation of cycle threshold value with severity of COVID-19 at the isolation of new emerging and re-emerging infectious diseases room Arifin Achmad General Hospital Riau Province Indonesia
10.1111/resp.14150_289 |
| 190 | P5-83: The correlation between cycle threshold polymerase chain reaction COVID-19 with the extent of chest X-ray abnormalities and D-dimer in COVID-19 patients at Arifin Achmad General Hospital Riau Province
10.1111/resp.14150_290 |
| 190 | P5-84: A case of organizing pneumonia caused by sclerosing agent used in endoscopic injection sclerotherapy
10.1111/resp.14150_291 |
| 191 | P5-85: Staged treatment of middle lobe lung gangrene using the vacuum-assisted closure therapy in a patient with severe COVID-19 pneumonia
10.1111/resp.14150_292 |
| 191 | P5-86: The effect of N-acetylcysteine inhalation on tumor necrosis factor-Α and cough severity score in community acquired pneumonia
10.1111/resp.14150_293 |
| 191 | P5-87: Time course of oxygen demand in patients with COVID-19 pneumonia
10.1111/resp.14150_294 |
| 192 | P5-88: Study of C reactive protein (HS-CRP) in post COVID-19 geriatric patients
10.1111/resp.14150_295 |
| 192 | P5-89: Effectiveness of a questionnaire to screen COVID-19
10.1111/resp.14150_296 |
| 192 | P5-90: Association of persistent and delayed symptoms with pneumonia in COVID-19
10.1111/resp.14150_297 |
| 193 | P5-91: Clinical characteristics and mortality risk in patients with severe COVID-19
10.1111/resp.14150_298 |
| 193 | P5-92: Respiratory viruses during COVID-19 pandemic in Okinawa, Japan
10.1111/resp.14150_299 |
| 194 | P5-93: Therapeutic effectiveness and tolerability of favipiravir in mild COVID-19: Real world experience from India
10.1111/resp.14150_300 |
| 194 | P5-94: The usefulness of a combination of age, body mass index, and blood urea nitrogen as prognostic factors in predicting oxygen requirements in patients with coronavirus disease 2019
10.1111/resp.14150_301 |
| 194 | P5-95: Complete heart block and neutropenia due to SARS - Corona virus-2 in a patient with chronic lymphocytic leukemia - Misery of an elderly gentleman
10.1111/resp.14150_302 |
| 195 | P5-96: Giant lung abscess following tooth extraction in an immunocompetent patient
10.1111/resp.14150_303 |
| 196 | P5-97: High-dose methylprednisolone in combination with tocilizumab in hospitalized patients with critical COVID-19 pneumonia: A case series
10.1111/resp.14150_304 |
| 196 | P5-98: Vitamin D deficiency as a marker of severe COVID-19 course
10.1111/resp.14150_305 |
| 196 | P5-99: The successful of intrapleural alteplase and pulmozyme in treating rhodococcus empyema in an immunocompromised patient
10.1111/resp.14150_306 |
| 197 | P5-100: A rare case of endobronchial actinomycosis responding to short course of antibiotics
10.1111/resp.14150_307 |
| 197 | P5-101: A case report of COVID-19 in an adult filipino with HIV-associated histoplasmosis
10.1111/resp.14150_308 |
| 198 | P5-102: Chronic pulmonary melioidosis in a 9 year old child
10.1111/resp.14150_309 |
| 198 | P5-103: Post covid cavitatory lung lesions: Individualised approach
10.1111/resp.14150_310 |
| 199 | P5-104: Reinfection of COVID-19 critical condition in miliary tuberculosis case with multiple comorbidities
10.1111/resp.14150_311 |
| 199 | P5-105: Relationship of total thrombocyte, lymphocyte account and PLR (platelet lymphocyte ratio) to severity degree of COVID-19 patients in ward
10.1111/resp.14150_312 |
| 200 | P5-106: Japanese, multicenter, phase II trial of combination therapy with favipiravir and methylprednisolone for COVID-19 patients with non-critical respiratory failure: the J-critical trial
10.1111/resp.14150_313 |
| 200 | P5-107: Disseminated non-tuberculous mycobacterium in an anti-IFN-gamma antibody positive patient
10.1111/resp.14150_314 |
| 201 | P5-108: The association between awake prone positioning and mortality in COVID-19 patients
10.1111/resp.14150_315 |
| 201 | P5-109: A fatal case of multiple mycotic pulmonary artery aneurysms due to Aspergillus terreus in a post COVID-19 patient
10.1111/resp.14150_316 |
| 202 | P5-110: Safety and efficacy confirmation study of PanbioTM COVID-19 Ag Rapid Test Device KIT operation by specimen self-collection
10.1111/resp.14150_317 |
| 202 | P5-111: SARS-CoV-2 PCR and antigen positivity continued for 3 months after treatment for severe COVID-19: Case report
10.1111/resp.14150_318 |
| 202 | P5-112: The relationship of chest X-ray in COVID-19 patients towards disease severity at Arifin Achmad Regional General Hospital, Riau Province
10.1111/resp.14150_319 |
| 203 | P5-113: Baseline characteristics, clinical course and outcomes of COVID-19 confirmed healthcare workers in the University of Santo Tomas Hospital
10.1111/resp.14150_320 |
| 203 | P5-114: A young lady with bones in the lungs –A case of diffuse pulmonary fibro ossification complicated with fungal infection
10.1111/resp.14150_321 |
| 204 | P5-115: A case report on invasive aspergillosis in an immunocompetent male
10.1111/resp.14150_322 |
| 204 | P5-116: Challenges in diagnosis of melioidosis in a child presented with uncomplicated community acquired pneumonia
10.1111/resp.14150_323 |
| 205 | P5-117: A case of bronchiolitis obliterans post influenza a pneumonia in adults
10.1111/resp.14150_324 |
| 205 | P5-118: Clinical outcomes of diffuse alveolar damage and organising pneumonia in severe COVID-19 infection
10.1111/resp.14150_325 |
| 206 | P5-119: Community acquired pneumonia secondary to multidrug resistant Pseudomonas luteola: A case report
10.1111/resp.14150_326 |
| 206 | P5-120: Withdrawn
10.1111/resp.14150_327 |
| 206 | P5-121: Inhaled beclomethasone in the treatment of early COVID-19: A placebo-controlled, randomized trial
10.1111/resp.14150_328 |
| 207 | P5-122: A case of secondary organizing pneumonia caused by relapse of inflammation after COVID-19 treatment with systemic corticosteroid and tocilizumab
10.1111/resp.14150_329 |
| 207 | P5-123: The clinical features and outcomes of discharged SARS-CoV-2 patients: A prospective cohort study
10.1111/resp.14150_330 |
| 208 | P5-124: Analysis of chemotherapy history and absolute neutrophil count to antibody antimannan in lung cancer patients with candidiasis
10.1111/resp.14150_331 |
| 208 | P5-125: Abrupt cessation of systemic corticosteroid in coronavirus disease 19 (COVID-19) related secondary organizing pneumonia resulted in a rebound
10.1111/resp.14150_332 |
| 209 | P5-126: Absolute lymphocyte count and neutrophil lymphocyte ratio as biomarker for candidiasis in lung cancer patients
10.1111/resp.14150_333 |
| 209 | P5-127: Clinical characteristics of SARS-CoV-2 infected (COVID-19) patients and mutant viral strains in rural area of Japan
10.1111/resp.14150_334 |
| 209 | P5-128: Study on lung abscess: A single centre experience in national hospital for respiratory diseases Sri Lanka
10.1111/resp.14150_335 |
| 210 | P5-129: Community-acquired methicillin-resistant Staphylococcus aureus pneumonia in a previously healthy 12-year-old male
10.1111/resp.14150_336 |
| 210 | P5-130: Scrub typhus complicated with pneumonitis and myocarditis; potentially a fatal complication
10.1111/resp.14150_337 |
| 211 | P5-131: Melioidosis presenting as hoarseness of voice
10.1111/resp.14150_338 |
| 212 | P5-132: Rehabilitation interventions and tasks for patients with COVID-19 in our hospital
10.1111/resp.14150_339 |
| 212 | P5-133: Invasive pulmonary aspergillosis mimicking lung malignancy
10.1111/resp.14150_340 |
| 213 | P5-134: Persistent cough in a diabetic due to invasive aspergillosis – A case report
10.1111/resp.14150_341 |
| 214 | P5-135: D-dimer as a predictor severity and mortality in hospitalized COVID-19 patients at Saiful Anwar General Hospital Malang
10.1111/resp.14150_342 |
| 214 | P5-136: The correlation between leucocyte, lymphocyte, thrombocyte, and sofa score on the severity of COVID-19 patients hospitalized in the PINERE Ward of Saiful Anwar Hospital
10.1111/resp.14150_343 |
| 214 | P5-137: Corona virus disease (COVID 19) in human immunodeficiency virus (HIV) patient
10.1111/resp.14150_344 |
| 215 | P5-138: Correlation between brixia score and RTPCR-SARS-CoV-2 result of pediatric patients with suspected or confirmed COVID-19 infection seen at Chong Hua Hospital, Cebu City from March 2020 to February 2021
10.1111/resp.14150_345 |
| 215 | P5-139: Melioidosis complicated with pyopneumothorax as a Mycobacterium tuberculosis mimic
10.1111/resp.14150_346 |
| 215 | P5-140: Solitary pulmonary cryptococcoma mimicking lung malignancy in an immunocompetent patient
10.1111/resp.14150_347 |
| 216 | P5-141: Invasive pulmonary aspergillosis in a case of metastatic lung adenocarcinoma: Challenges in diagnosis and treatment
10.1111/resp.14150_348 |
| 217 | P5-142: A case series on corticosteroid use in COVID-19 patients who suffered from chronic lung disease
10.1111/resp.14150_349 |
| 217 | P5-143: Post-corona virus disease 2019 (COVID-19) pneumothorax
10.1111/resp.14150_350 |
| 217 | P5-144: Infected pneumatoceles complicating the course of COVID-19 pneumonia
10.1111/resp.14150_351 |
| 218 | P5-145: COVID-19: Performance of oseltamivir and isoprinosine in neutrophil-to-lymphocyte ratio improvement from confirmed COVID-19 patients in Saiful Anwar General Hospital, Malang
10.1111/resp.14150_352 |
| 218 | P5-146: A case of Mycobacterium szulgai with hypothyroidism and electrolyte abnormalities
10.1111/resp.14150_353 |
| 219 | P5-147: Pulmonary cryptococcosis in an immunocompromised patient diagnosed by cryobiopsy
10.1111/resp.14150_354 |
| 219 | P5-148: The correlation between RT-PCR and antibody rapid test in SARS CoV-2
10.1111/resp.14150_355 |
| 219 | P5-149: Investigation of antibody level by the presence or absence of side effects after the new coronavirus vaccine
10.1111/resp.14150_356 |
| 220 | P5-150: COVID-19 patients with a late diagnosis of HIV
10.1111/resp.14150_357 |
| 220 | P5-151: Changes over time in six-minute walk test and the SGRQ scores in patients with nontuberculous mycobacterial pulmonary disease
10.1111/resp.14150_358 |
| 221 | P5-152: Familial ciclesonide-responsive cases of COVID-19 pneumonia
10.1111/resp.14150_359 |
| 221 | P5-153: Diagnostic performance of computed tomography imaging for COVID-19 in a region with low disease prevalence
10.1111/resp.14150_360 |
| 221 | P5-154: A case of bilateral recurrent exudative pyogenic pleural effusion
10.1111/resp.14150_361 |
| 222 | P5-155: Legionella pneumophilia pneumonia with rapid clinical course in a lung cancer patient
10.1111/resp.14150_362 |
| 222 | P5-156: Pneumomediastinum in COVID-19 confirmed case: A rare case
10.1111/resp.14150_363 |
| 222 | P5-157: Adverse event following COVID-19 vaccination and antibody titers in pulmonologists and pulmonology residents
10.1111/resp.14150_364 |
| 223 | P5-158: Examination of correspondence to COVID-19 patients in our hospital
10.1111/resp.14150_365 |
| Tuberculosis | |
| 223 | P6-1: Impact of COVID-19 on the epidemiology of TB among migrants in Japan
10.1111/resp.14150_367 |
| 223 | P6-2: To study the efficacy and safety of bedaquiline plus optimized background regimen and high dose moxifloxacin plus optimized background regimen in drug resistant pulmonary tuberculosis-A prospective observational study
10.1111/resp.14150_368 |
| 224 | P6-3: Efficacy and safety of levamisole as an immunomodulator in the treatment of pulmonary drug-resistant tuberculosis
10.1111/resp.14150_369 |
| 224 | P6-4: Endobronchial mass occurred during treatment of tuberculosis: Two cases
10.1111/resp.14150_370 |
| 226 | P6-5: Impact of COVID-19 on tuberculosis in Japan; A national database analysis
10.1111/resp.14150_371 |
| 226 | P6-6: Anti tuberculosis treatment induced drug rash with eosinophilia and systemic symptoms (DRESS) mimicking meningitis
10.1111/resp.14150_372 |
| 227 | P6-7: Is nontuberculous mycobacterial lung disease a risk factor of latent tuberculous infection? - A prospective study in a medical center
10.1111/resp.14150_373 |
| 227 | P6-8: Abandonment of tuberculosis treatment in patients with mental health disorders in Brazil
10.1111/resp.14150_374 |
| 228 | P6-9: A post covid activation of latent tuberculosis
10.1111/resp.14150_375 |
| 229 | P6-10: Mysterious nodule in the spermatic cord in an immunosuppressed patient – An executive's agony
10.1111/resp.14150_376 |
| 229 | P6-11: Higher bacterial load in drug resistant tuberculosis leads to unfavourable treatment outcome
10.1111/resp.14150_377 |
| 229 | P6-12: The cruel dual; SARS-CoV-2 and tuberculosis co-infection, the Sri Lankan experience
10.1111/resp.14150_378 |
| 230 | P6-13: Clinical impact of low body mass index in patients with Mycobacterium avium complex pulmonary disease
10.1111/resp.14150_379 |
| 230 | P6-14: Impact of nationwide lockdown due to COVID 19 on incidence of sputum positive pulmonary tuberculosis in rural India
10.1111/resp.14150_380 |
| 231 | P6-15: Cardiotoxicity in drug-resistant tuberculosis patients treated with short term regiment
10.1111/resp.14150_381 |
| 231 | P6-16: TB salphingitis in a background of endometriosis – A rare association
10.1111/resp.14150_382 |
| 231 | P6-17: Effectiveness of inhaled hypertonic saline application for sputum induction to improve Mycobacterium tuberculosis (MTB) identification in patients with pulmonary tuberculosis
10.1111/resp.14150_383 |
| 232 | P6-18: Endobronchial ultrasound transbronchial aspiration biopsy (EBUS-TBNA) in the diagnosis of mediastinal mass of unknown etiology: A case series
10.1111/resp.14150_384 |
| 232 | P6-19: Clinical characteristics of pulmonary tuberculosis in the central and eastern part of Shizuoka
10.1111/resp.14150_385 |
| 233 | P6-20: The clinical characteristics of MAC-PD patients with negative serum anti-glycopeptidolipid-core IgA antibody results
10.1111/resp.14150_386 |
| 233 | P6-21: A case of tuberculous pleurisy masquerading malignant lymphoma
10.1111/resp.14150_387 |
| 234 | P6-22: Characteristics of pulmonary tuberculosis with delayed diagnosis in our hospital
10.1111/resp.14150_388 |
| 234 | P6-23: Diagnostic utility of adenosine deaminase (ADA) activity in pleural fluid and pleural fluid lactate dehydrogenase/ADA ratio of tuberculous and non-tuberculous pleural disease
10.1111/resp.14150_389 |
| 235 | P6-24: co-existence of active pulmonary tuberculosis and aspergilloma- a rare entity
10.1111/resp.14150_390 |
| 235 | P6-25: Thrombophlebitis and deep vein thrombosis, a rare presentation of tuberculosis
10.1111/resp.14150_391 |
| 236 | P6-26: Screening for tuberculosis among persons with diabetes mellitus in metro Manila, Philippines: A multi-center study
10.1111/resp.14150_392 |
| 236 | P6-27: Intrapleural alteplase and DNase for complex tuberculous pleural effusion
10.1111/resp.14150_393 |
| 237 | P6-28: Clinical case of using intravenous forms of anti-tuberculosis drugs to improve the treatment efficiency of tuberculosis in patients with malabsorption syndrome (MS)
10.1111/resp.14150_394 |
| 237 | P6-29: A case of elderly female with unresponsive anti-tuberculosis therapy in rural area
10.1111/resp.14150_395 |
| 238 | P6-30: Pulmonary tuberculosis presents radiologically as Kaposi sarcoma: A case report
10.1111/resp.14150_396 |
| 239 | P6-31: CD4+ MAIT cells in blood of patients may enhanced anti-tuberculosis function by increasing IFN-Γ and granzyme b production
10.1111/resp.14150_397 |
| 239 | P6-32: Clinical efficacy of endobronchial ultrasonography in the diagnosis of mycobacterial infections
10.1111/resp.14150_398 |
| 239 | P6-33: Evaluation of sustained treatment success rate of tuberculosis patients in Japan
10.1111/resp.14150_399 |
| 240 | P6-34: Prevalence of rifampicin resistance in patients with pulmonary tuberculosis in western India using automated TrueNat assay
10.1111/resp.14150_400 |
| 240 | P6-35: The predicament in diagnosing Mycobacterium tuberculosis in young patients
10.1111/resp.14150_401 |
| 241 | P6-36: Components system of nitric oxide as markers of pulmonary multi-drug resistant tuberculosis process activity
10.1111/resp.14150_402 |
| 241 | P6-37: The difficult diagnosis of a common disease
10.1111/resp.14150_403 |
| 242 | P6-38: Utility of thoracoscopy under local anesthesia in the diagnosis of tuberculous pleurisy and drug susceptibility testing for tuberculosis
10.1111/resp.14150_404 |
| 242 | P6-39: A case of consecutive pneumocystis pneumonitis and varicella pneumonia during the treatment of miliary tuberculosis
10.1111/resp.14150_405 |
| 242 | P6-40: Tuberculosis involving the subcutaneous tissue adjacent to Achilles tendon – A rare presentation
10.1111/resp.14150_406 |
| 243 | P6-41: Rifampicin resistant pulmonary tuberculosis with concomitant bacterial pneumonia. Showing left lower lobe consolidation in the young and immunocompetent physician
10.1111/resp.14150_407 |
| 243 | P6-42: A case of extensively drug-resistant tuberculosis (XDR TB) unresponsive to many drug regimes: A treatment dilemma
10.1111/resp.14150_408 |
| 244 | P6-43: Multicenter Prospective Study on Gouty Arthritis and Predictors of Outcomes among Filipino Patients on Anti-Tuberculosis Treatment
10.1111/resp.14150_409 |
| 245 | P6-44: Case report of a newly diagnosed bacteriologically confirmed pulmonary tuberculosis in a patient with COVID-19 critical infection
10.1111/resp.14150_410 |
| 245 | P6-45: A case of multi-drug resistant tuberculosis (MDR-TB), presenting an abscess of the left leg in a trainee of nursing care visiting in Japan from Myanmar
10.1111/resp.14150_411 |
| 246 | P6-46: Long-term pass holders with multidrug-resistant tuberculosis (MDR-TB) in Singapore: missed opportunities for earlier diagnosis
10.1111/resp.14150_412 |
| 246 | P6-47: Adverse drug reactions and their impact on the treatment of pulmonary tuberculosis in elderly patients
10.1111/resp.14150_413 |
| 246 | P6-48: Unilateral hypoplastic lung complicated with pulmonary tuberculosis – A rare association
10.1111/resp.14150_414 |
| 247 | P6-49: Association of interleukins genes polymorphisms with MDR TB in Kharkiv Region, Ukraine
10.1111/resp.14150_415 |
| 247 | P6-50: Primary multidrug-resistant tuberculosis in coronavirus disease 2019
10.1111/resp.14150_416 |
| 248 | P6-51: Primary pulmonary multi-drug resistant tuberculosis on silicotic lung
10.1111/resp.14150_417 |
| 248 | P6-52: Pediatric tuberculosis presenting with chest wall abscess
10.1111/resp.14150_418 |
| 249 | P6-53: A study of liver dysfunction due to combined use of PZA in elderly pulmonary tuberculosis
10.1111/resp.14150_419 |
| 249 | P6-54: Tubercular mastitis - The great masquerader
10.1111/resp.14150_420 |
| 250 | P6-55: Peritoneal deposits with a hilar lesion due to tuberculosis – A great masquerader
10.1111/resp.14150_421 |
| 250 | P6-56: One case of a patient on maintenance dialysis who concurrently suffered from both COVID-19 and a relapse of pulmonary tuberculosis
10.1111/resp.14150_422 |
| 250 | P6-57: Case report Heimlich valve as an ambulation management of persistent pneumothorax in patient with pulmonary tuberculosis
10.1111/resp.14150_423 |
| 251 | P6-58: Pneumothorax as a clinical manifestation of lung tuberculosis with co-infection COVID-19 and bacterial pneumonia
10.1111/resp.14150_424 |
| 251 | P6-59: The age and outcomes of patients with tuberculosis in our hospital: A 30-year single-institution experience
10.1111/resp.14150_425 |
| 252 | P6-60: Characteristics of tuberculous and malignant pleural effusion patients in Sanglah Hospital Denpasar, Indonesia
10.1111/resp.14150_426 |
| 252 | P6-61: Association of serum antibodies against the Mycobacterium avium complex with hemoptysis
10.1111/resp.14150_427 |
| 252 | P6-62: Squamous cell carcinoma of the palate in a patient with pulmonary tuberculosis getting complicated with exfoliative dermatitis – A case report
10.1111/resp.14150_428 |
| 253 | P6-63: Disseminated TB? disseminated malignancy? or both? a diagnostic trilemma
10.1111/resp.14150_429 |
| 254 | P6-64: The great masquerader: A case of tuberculous effusion and coexisting lung adenocarcinoma diagnosed through pleural biopsy
10.1111/resp.14150_430 |
| 255 | P6-65: A case of tuberculosis infection with a particular clinical course and difficulty in treatment
10.1111/resp.14150_431 |
| 255 | P6-66: The effect of Miana leaves on HIF-1Α protein expression in Balb/C mice infected with mycobacterium tuberculosis
10.1111/resp.14150_432 |
| 255 | P6-67: Study on sputum non-conversion at the end of intensive phase in smear positive pulmonary tuberculosis patients
10.1111/resp.14150_433 |
| COPD | |
| 256 | P7-1: Spontaneous pulmonary emphysema in mice lacking all three nitric oxide synthase isoforms
10.1111/resp.14150_435 |
| 257 | P7-2: Diaphragmatic excursion is correlated with the improvement in exercise tolerance after pulmonary rehabilitation in COPD patients
10.1111/resp.14150_436 |
| 257 | P7-3: Exposure to the heated tobacco product IQOS generates apoptosis-mediated pulmonary emphysema in murine lungs
10.1111/resp.14150_437 |
| 258 | P7-4: The level of TLR2 expression on circulating CD4+ cells as a diagnostic biomarker of chronic obstructive pulmonary disease
10.1111/resp.14150_438 |
| 258 | P7-5: Sex-specific differences of prevalence and risk factors for chronic obstructive pulmonary disease in subjects with preserved ratio impaired spirometry
10.1111/resp.14150_439 |
| 258 | P7-6: The association between alkaline phosphatase and COPD symptoms, severity, and exacerbation
10.1111/resp.14150_440 |
| 258 | P7-7: Effect of periodontal pathogen Fusobacterium nucleatum on a COPD mouse model
10.1111/resp.14150_441 |
| 259 | P7-8: Effect of surgical mask on exercise capacity in patients with chronic obstructive pulmonary disease: A randomized controlled trial
10.1111/resp.14150_442 |
| 259 | P7-9: Involvement of Parkin-mediated mitophagy in COPD-related sarcopenia pathogenesis
10.1111/resp.14150_443 |
| 260 | P7-10: Relationship of quantitative chest computed tomography with clinical characteristics and functional exercise capacity in chronic obstructive pulmonary disease
10.1111/resp.14150_444 |
| 261 | P7-11: Influence of chronic obstructive pulmonary disease in promoting arteriosclerosis in smokers
10.1111/resp.14150_445 |
| 261 | P7-12: Sirtuin3 suppresses lung inflammation of COPD exacerbation mouse model
10.1111/resp.14150_446 |
| 262 | P7-13: Identification of exacerbation phenotypes across asthma and COPD
10.1111/resp.14150_447 |
| 262 | P7-14: Longitudinal changes of disease probability measure parameters in COPD
10.1111/resp.14150_448 |
| 263 | P7-15: Biochemical markers of endothelial dysfunction in patients with chronic obstructive diseases of the lungs of different categories of risk of exacerbations
10.1111/resp.14150_449 |
| 263 | P7-16: Clinical utility of the electrocardiographic P-wave axis in patients with chronic obstructive pulmonary disease
10.1111/resp.14150_450 |
| 263 | P7-17: One-year clinically important deterioration and long-term clinical course in Japanese patients with COPD
10.1111/resp.14150_451 |
| 264 | P7-18: Latent classes of cough phenotypes in middle-aged adults: Tasmanian longitudinal health study
10.1111/resp.14150_452 |
| 265 | P7-19: Associations of body compositions with airflow limitation and exercise-induced dynamic hyperinflation in patients with chronic obstructive pulmonary disease
10.1111/resp.14150_453 |
| 265 | P7-20: Small airway dysfunction predict decline in FEV1: Results from a cross-sectional study in Shanghai, China
10.1111/resp.14150_454 |
| 265 | P7-21: Сhronic obstructive pulmonary disease, cataract and oxidative stress
10.1111/resp.14150_455 |
| 266 | P7-22: Characteristics of nocturnal desaturation waveform pattern of SPO2 in COPD patients
10.1111/resp.14150_456 |
| 266 | P7-23: Effectiveness of combination therapy with selective beta-1 blockers and pulmonary rehabilitation for COPD
10.1111/resp.14150_457 |
| 267 | P7-24: Up-regulation of LIM/homeobox protein LHX9 in alveolar epithelial type 2 cells of COPD lungs
10.1111/resp.14150_458 |
| 267 | P7-25: The mortality difference in chronic obstructive pulmonary disease: Ever-smoker versus never-smoker
10.1111/resp.14150_459 |
| 268 | P7-26: Cognitive functions in stable patients with chronic obstructive pulmonary disease compared to healthy volunteers assessed using PGI memory scale
10.1111/resp.14150_460 |
| 268 | P7-27: Biologics for the treatment of COPD with increased peripheral blood eosinophils: A systematic review and meta-analysis
10.1111/resp.14150_461 |
| 269 | P7-28: Changes of forced vital capacity are associated with poor outcome in asthma-COPD overlap
10.1111/resp.14150_462 |
| 269 | P7-29: Muscle mass evaluation using body composition analysis for COPD patients
10.1111/resp.14150_463 |
| 269 | P7-30: Expression profile of microRNAS in serum extracellular vesicles of COPD frequent exacerbators
10.1111/resp.14150_464 |
| 270 | P7-31: The role of KIAA1462 in chronic obstructive pulmonary disease (COPD)
10.1111/resp.14150_465 |
| 270 | P7-32: The frailty and the physical activity in COPD patients: cross-sectional study
10.1111/resp.14150_466 |
| 271 | P7-33: The different significance between sedentary time and high-intensity physical activities in patients with stable COPD
10.1111/resp.14150_467 |
| 271 | P7-34: Impact of pulmonary rehabilitation on pulmonary function measures, exercise capacity, quality of life and psychosocial parameters in patients with chronic obstructive pulmonary disease
10.1111/resp.14150_468 |
| 272 | P7-35: Quantitative CT-based evaluation of skeletal muscle and presence of sarcopenia in patients with chronic obstructive pulmonary disease
10.1111/resp.14150_469 |
| 272 | P7-36: The effect of nutritional status on exacerbation in COPD patients: A retrospective and prospective cohort study
10.1111/resp.14150_470 |
| 273 | P7-37: The characteristics of responders to treatment with tiotropium/olodaterol: A large cohort post-marketing surveillance post-hoc analysis in Japan
10.1111/resp.14150_480 |
| 273 | P7-38: Interleukin-6 and interleukin-8 in patients with chronic obstructive lung disease with different risk of exacerbations
10.1111/resp.14150_481 |
| 274 | P7-39: Evaluation of the effect of ICS containing triple therapy with LAMA/LABA in comparison with LAMA/LABA in COPD patients
10.1111/resp.14150_482 |
| 274 | P7-40: Assessment of the screening strategy of early detection of COPD
10.1111/resp.14150_483 |
| 274 | P7-41: Risk factors for mortality and readmission in patients hospitalized with congestive heart failure and chronic obstructive pulmonary disease
10.1111/resp.14150_484 |
| 275 | P7-42: Significance of monitoring patients with chronic obstructive pulmonary disease during walking rehabilitation by transcutaneous blood gas analysis
10.1111/resp.14150_485 |
| 275 | P7-43: The impact of fungal sensitization on clinical features in asthma and chronic pulmonary obstructive disease
10.1111/resp.14150_486 |
| 275 | P7-44: Involvement of airway hyperresponsiveness in the therapy for COPD
10.1111/resp.14150_487 |
| 276 | P7-45: Non-pulmonary medicine specialists' knowledge, attitude and practice in the diagnosis of chronic obstructive pulmonary disease (COPD) in a Tertiary Hospital in Manila, Philippines
10.1111/resp.14150_488 |
| 276 | P7-46: Airflow obstruction on spirometry in patients undergoing surgery using general anesthesia
10.1111/resp.14150_489 |
| 276 | P7-47: Blood eosinophil count as a predictive biomarker of COPD exacerbation in a real-world setting
10.1111/resp.14150_490 |
| 277 | P7-48: Usefulness of non-exercise activity thermogenesis (NEAT) score to estimate physical activity level in patients with COPD
10.1111/resp.14150_491 |
| 277 | P7-49: Clinical experience of budesonide/glycopyrrolate/formoterol in patients with chronic obstructive pulmonary disease
10.1111/resp.14150_492 |
| 277 | P7-50: Air pollution and mortality in chronic obstructive pulmonary disease (COPD) patients
10.1111/resp.14150_493 |
| 278 | P7-51: The effect of increased frequency of home-based upper-extremity strength and endurance training, and additional egg-white diet on COPD patients' fat-free muscle mass
10.1111/resp.14150_494 |
| 279 | P7-52: The effectiveness of home-based upper arm endurance and strength exercises with eggwhite supplementation on functional capacity and quality of life in stable COPD patients
10.1111/resp.14150_495 |
| 279 | P7-53: Association between vitamin D level and respiratory symptom in patients with stable chronic obstructive pulmonary disease
10.1111/resp.14150_496 |
| 280 | P7-54: Association of cat score with PFT and 6 minute walk test in assessing the severity of COPD
10.1111/resp.14150_497 |
| 280 | P7-55: One-year follow-up of instruction in inhalation technique for chronic obstructive pulmonary disease patients
10.1111/resp.14150_498 |
| 280 | P7-56: Evaluation of useful guide to which cases ICS should be added in combination with a long-acting bronchodilator in the patients with chronic obstructive pulmonary disease
10.1111/resp.14150_499 |
| 281 | P7-57: The effectiveness of home-based upper-body strength and endurance training pulmonary rehabilitation program on the muscle mass of stable COPD patients
10.1111/resp.14150_500 |
| 281 | P7-58: Inhaler adherence and technique in patients of chronic obstructive pulmonary disease at Pham Ngoc Thach Hospital, Ho Chi Minh City
10.1111/resp.14150_501 |
| 282 | P7-59: Relationship between stable chronic obstructive pulmonary disease with the incidence of heart failure and its influencing factors in the lung polyclinic at Arifin Achmad General Hospital, Riau Province
10.1111/resp.14150_502 |
| 282 | P7-60: The effectiveness of strength and resistance exercise of the upper extremity on muscle mass in chronic obstructive pulmonary diseases patients
10.1111/resp.14150_503 |
| 283 | P7-61: Management & caring for patients of COPD with COVID-19: A current perspective
10.1111/resp.14150_504 |
| 283 | P7-62: Face mask protective or trigger for exacerbation in COPD patients
10.1111/resp.14150_505 |
| 284 | P7-63: Real world comparative effectiveness and tolerability of glycopyrronium/formoterol (G/F – 25 μG/12 μG) versus glycopyrronium/formoterol (G/F – 25 μG/6 μG) dry powder inhaler in COPD patients – Retrospective study
10.1111/resp.14150_506 |
| 284 | P7-64: Comparative effectiveness of glycopyrronium monotherapy vs ICS/LABA in drug-naïve mild-moderate COPD patients: A real world experience from INDIA
10.1111/resp.14150_507 |
| 285 | P7-65: Correlation between body mass index (BMI) and chronic obstructive pulmonary disease (COPD)
10.1111/resp.14150_508 |
| 285 | P7-66: Clinical inertia in the management of COPD: A review of the literature
10.1111/resp.14150_509 |
| 285 | P7-67: The association between history of respiratory infection in childhood and the incidence of COPD
10.1111/resp.14150_510 |
| 286 | P7-68: The association of history respiratory infection in childhood and level epidermal growth factor in COPD
10.1111/resp.14150_511 |
| Lung Cancer | |
| 286 | P8-1: Differential expression of miR-375 and miR-455-3p is related to molecular subtyping of small cell lung cancer
10.1111/resp.14150_513 |
| 287 | P8-2: The new scoring system for predicting in-hospital death after lung cancer surgery (the SABCIP Score) using a Japanese Nationwide Administrative Database
10.1111/resp.14150_514 |
| 287 | P8-3: Gene amplification of ACTN4 is a predictive biomarker for the adjuvant chemotherapy with uracil-tegafur in stage-I patients with adenocarcinoma of the lung
10.1111/resp.14150_515 |
| 288 | P8-4: An integrated analysis of the competing endogenous RNA network associated of prognosis of stage I lung adenocarcinoma
10.1111/resp.14150_516 |
| 288 | P8-5: Quantification of visible her family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with EGFR-TKI
10.1111/resp.14150_517 |
| 289 | P8-6: Cross-talk between erasers and readers of N6-methyladenosine regulates cell proliferation in non-small cell lung cancer
10.1111/resp.14150_518 |
| 289 | P8-7: Antigen-presenting capacity of fibrocytes and its regulation by anti-PD-1/PD-L1 antibodies
10.1111/resp.14150_519 |
| 290 | P8-8: Construction of lncRNA prognostic risk model for lung adenocarcinoma
10.1111/resp.14150_520 |
| 290 | P8-9: Genomics on circulating tumor DNA predicts survival under afatinib treatment for EGFR- mutated non-small cell lung cancer
10.1111/resp.14150_521 |
| 291 | P8-10: Minichromosome maintenance complex component (MCM) genes in lung adenocarcinoma: MCM-family acts as a potential therapeutic target
10.1111/resp.14150_522 |
| 291 | P8-11: Inhibition of the bax and bak apoptotic function by paclitaxel prevents genotoxic cell death in gefitinib-resistant non-small-cell lung cancer
10.1111/resp.14150_523 |
| 291 | P8-12: The relationship between lung microbiota and pathologic subtype with prognosis
10.1111/resp.14150_524 |
| 292 | P8-13: The gut microbiome as a new marker of tumor progression among female never-smokers with lung adenocarcinoma
10.1111/resp.14150_525 |
| 292 | P8-14: Development of an optimal protocol for molecular profiling of tumor cells in malignant pleural effusions at single-cell level
10.1111/resp.14150_526 |
| 292 | P8-15: Usefulness of liquid biopsy for patients with non-small cell lung cancer harboring an EGFR mutation treated with afatinib
10.1111/resp.14150_527 |
| 293 | P8-16: An exploratory study of biomarkers in blood of osimertinib for EGFR-T790M mutation-positive NSCLC
10.1111/resp.14150_528 |
| 293 | P8-17: Efficacy of first line pembrolizumab in recurrent non-small cell lung cancer after curative intent treatment
10.1111/resp.14150_529 |
| 294 | P8-18: Analysis of trace element concentrations and relationship between trace element and prognosis in lung cancer patients
10.1111/resp.14150_530 |
| 294 | P8-19: The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials
10.1111/resp.14150_531 |
| 295 | P8-20: Postoperative radiotherapy prolongs survival of completely resected Masaoka/Masaoka-Koga stage II/III thymoma
10.1111/resp.14150_532 |
| 295 | P8-21: Heterogeneity among tumors with acquired resistance to EGFR-TKIs harboring EGFR-T790M mutation in non-small cell lung cancer cells
10.1111/resp.14150_533 |
| 295 | P8-22: Solo surgery style. benefits and technical points of robot-assisted respiratory surgery
10.1111/resp.14150_534 |
| 296 | P8-23: Clinical importance of LINC00460 expression in EGFR mutation-positive lung cancer treated with osimertinib
10.1111/resp.14150_535 |
| 296 | P8-24: The miR-124-3P/ZFP36L1 axis is suppressed by ASCL1 in lung adenocarcinoma
10.1111/resp.14150_536 |
| 296 | P8-25: Type A CPG oligodeoxynucleotide competitively inhibits IFN-Γ receptors in human lung cancer cells
10.1111/resp.14150_537 |
| 297 | P8-26: Study of the number of courses required for the first response to immune checkpoint inhibitor (+chemo) therapy for lung cancer
10.1111/resp.14150_538 |
| 297 | P8-27: A comprehensive retrospective analysis to assess the clinical impact of cerebral infarction in patients with non-small cell lung cancer
10.1111/resp.14150_539 |
| 298 | P8-28: A case of malignant pleural mesothelioma achieved improvement by specific substance of Maruyama
10.1111/resp.14150_540 |
| 298 | P8-29: Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in EGFR-mutant NSCLC with T790M mutation
10.1111/resp.14150_541 |
| 298 | P8-30: Usefulness of pulmonary rehabilitation in non-small cell lung cancer patients based on pulmonary function tests and muscle index analysis using computed tomography images
10.1111/resp.14150_542 |
| 299 | P8-31: Prospective observational study of sequential afatinib and osimertinib in NSCLC patients with EGFR mutation: Gio-Tag Japan
10.1111/resp.14150_543 |
| 299 | P8-32: Significance of positive blood culture in chemotherapy induced febrile neutropenia patients with lung cancer
10.1111/resp.14150_544 |
| 300 | P8-33: A case of enterocolitis with bleeding caused by osimertinib
10.1111/resp.14150_545 |
| 300 | P8-34: The relation between immune-related adverse events and therapeutic effects of nivolumab or pembrolizumab monotherapy for patients with non-small cell lung cancer
10.1111/resp.14150_546 |
| 300 | P8-35: Metronomic irinotecan and irinotecan plus everolimus induce angiogenesis inhibitory effect in human small cell lung cancer xenografts
10.1111/resp.14150_547 |
| 301 | P8-36: Withdrawn
10.1111/resp.14150_548 |
| 301 | P8-37: Delayed visit and treatment of lung cancer during the coronavirus disease 2019 pandemic in Japan
10.1111/resp.14150_549 |
| 301 | P8-38: Analysis of OncomineDx target test multi CDX system cases in Juntendo Hospital
10.1111/resp.14150_550 |
| 302 | P8-39: Current status and future challenges of lung cancer genomic medicine at Hiroshima University Hospital
10.1111/resp.14150_551 |
| 302 | P8-40: Efficacy of unscheduled discontinuation of durvalumab monotherapy after concurrent chemoradiotherapy in locally advanced unresectable non-small cell lung carcinoma: A single-center retrospective analysis
10.1111/resp.14150_552 |
| 302 | P8-41: A herbal medicine Ninjin-yoei-to ameliorates lung cancer cachexia in mice
10.1111/resp.14150_553 |
| 303 | P8-42: Expression of anti-Müllerian hormone type II receptor and antiproliferative effects of anti-müllerian hormone on human lung adenocarcinoma
10.1111/resp.14150_554 |
| 303 | P8-43: Retrospective study on timing of PET/CT scanning in pulmonary nodule management
10.1111/resp.14150_555 |
| 304 | P8-44: Predictive biomarker for the therapeutic effect of PD-L1 inhibitor maintenance therapy in patients with extensive-stage small-cell lung cancer
10.1111/resp.14150_556 |
| 304 | P8-45: ONO-7475, a novel AXL inhibitor, suppresses the emergence and maintenance of tolerant cells to initial EGFR-TKI treatment in EGFR-mutated non-small lung cancer
10.1111/resp.14150_557 |
| 305 | P8-46: Clinical impact of chemotherapy combined with pembrolizumab in elderly patients with advanced non-small-cell lung cancer
10.1111/resp.14150_558 |
| 305 | P8-47: Autoantibody positivity is a risk factor for chemotherapy-induced exacerbation of interstitial pneumonia in lung cancer
10.1111/resp.14150_559 |
| 305 | P8-48: Analyses of association between characteristics of patients with EGFR mutations and antitumor effect of ICIS after EGFR-TKIs
10.1111/resp.14150_560 |
| 306 | P8-49: Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small cell lung cancer
10.1111/resp.14150_561 |
| 306 | P8-50: Lung cancer, as a risk factor for abdominal aortic aneurysm (AAA)
10.1111/resp.14150_562 |
| 307 | P8-51: AIM2 overexpression and its relationship to KRAS mutations in non-small cell lung cancer
10.1111/resp.14150_563 |
| 307 | P8-52: Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease
10.1111/resp.14150_564 |
| 308 | P8-53: The effects of anticancer drugs on lymphocyte immune checkpoints
10.1111/resp.14150_565 |
| 308 | P8-54: Is combination chemotherapy with ICI and cytotoxic agents always better than monotherapy with ICI in patients with advanced NSCLC?
10.1111/resp.14150_566 |
| 308 | P8-55: A review of cases of gene panel testing using next-generation sequencers at our hospital
10.1111/resp.14150_567 |
| 309 | P8-56: Systemic anticancer therapy increases plasma levels of calreticulin and hmgb1 in patients with advanced lung cancer
10.1111/resp.14150_568 |
| 309 | P8-57: Current status of cancer genome profiling tests for thoracic malignancies
10.1111/resp.14150_569 |
| 310 | P8-58: Association between proton-pump inhibitors and the ABCG2 C421A polymorphism and plasma concentration of gefitinib
10.1111/resp.14150_570 |
| 310 | P8-59: Drebrin-positive tumor-infiltrating lymphocytes as a prognostic biomarker for lung squamus cell carcinoma
10.1111/resp.14150_571 |
| 310 | P8-60: Evaluation of the inter-tumor heterogeneity of PD-L1 expression in primary and metastatic lesions of autopsy cases with untreated lung adenocarcinoma
10.1111/resp.14150_572 |
| 311 | P8-61: Real world setting of malignant pleural mesothelioma post drug-approval of pemetrexed
10.1111/resp.14150_573 |
| 311 | P8-62: A phase II trial of osimertinib for elderly patients with epidermal growth factor receptor T790M-positive non-small cell lung cancer that progressed during previous treatment
10.1111/resp.14150_574 |
| 312 | P8-63: Impact of the lung immune prognostic index (LIPI) in limited disease small cell lung cancer patients treated with chemoradiotherapy
10.1111/resp.14150_575 |
| 312 | P8-64: Optimal dose of amrubicin for previously treated small-cell lung cancer: A retrospective study
10.1111/resp.14150_576 |
| 313 | P8-65: Integrin alpha 2 in non–small cell lung cancer is associated with tumor progression and postoperative recurrence
10.1111/resp.14150_577 |
| 313 | P8-66: Evaluation of atezolizumab monotherapy for chemotherapy-refractory patients with non-small cell lung cancer in clinical practice
10.1111/resp.14150_578 |
| 314 | P8-67: A retrospective study of recurrence patterns in chemoradiotherapy using volumetric modulated arc therapy for locally advanced non-small cell lung cancer
10.1111/resp.14150_579 |
| 314 | P8-68: Development of a potential biomarker for PD-L1 expression in lung carcinoma
10.1111/resp.14150_580 |
| 314 | P8-69: Clinical study of chemotherapy with an immune checkpoint inhibitor combination chemotherapy in advanced small cell lung cancer
10.1111/resp.14150_581 |
| 315 | P8-70: Correlation of tumour marker (CEA, Cyfra 21-1) with serial miRNA (miR-34, miR-222, miR-148 and miR-155) in advanced stage non-small cell lung cancer (NSCLC) in Indonesia
10.1111/resp.14150_582 |
| 315 | P8-71: Correlation of serum electrolyte with serial miRNA in advanced stage non-small cell lung cancer (NSCLC) in Indonesia
10.1111/resp.14150_583 |
| 315 | P8-72: A case of hemophagocytic lymphohistiocytosis during atezolizumab treatment for lung adenocarcinoma
10.1111/resp.14150_584 |
| 316 | P8-73: Diagnostic test of cancer ratio and pleural fluid red blood cell/adenosine deaminase ratio to identify malignant pleural effusion
10.1111/resp.14150_585 |
| 316 | P8-74: Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion
10.1111/resp.14150_586 |
| 317 | P8-75: First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large real-world cohort of non-small cell lung cancer patients
10.1111/resp.14150_587 |
| 317 | P8-76: Loss of glutathione S-transferase omega 2 caused by DNA hypermethylation is associated with progression of non-small cell lung cancer
10.1111/resp.14150_588 |
| 317 | P8-77: The relationship between incidence of acquired resistance (exon 20 T790M mutation) and RECIST 1.1 results in EGFR-TKI treatment of adenocarcinoma lung patients
10.1111/resp.14150_589 |
| 319 | P8-78: Different response for crizocinib treatment for lung adenocarcinoma patients with the rare variants of SDC4-ROS1 rearrangement
10.1111/resp.14150_590 |
| 318 | P8-79: A comparison study on validity of the risk of malignancy using three mathematical prediction models in patients with solitary pulmonary nodules-A single center retrospective cross-sectional study
10.1111/resp.14150_591 |
| 319 | P8-80: Bevacizumab suppresses epithelial-to-mesenchymal transition in EGFR-mutant lung cancer
10.1111/resp.14150_592 |
| 319 | P8-81: Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: A meta-analysis of individual patient data
10.1111/resp.14150_593 |
| 319 | P8-82: CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report
10.1111/resp.14150_594 |
| 320 | P8-83: Giant pleuro parenchymal metastases from a rare primary tumor
10.1111/resp.14150_595 |
| 321 | P8-84: S-1 reduces myeloid-derived suppressor cells in murine mesothelioma model and enhances the anti-tumor activity of anti-PD-1 antibody
10.1111/resp.14150_596 |
| 321 | P8-85: Analyses of lung sounds altered by cancers or surgical complications
10.1111/resp.14150_597 |
| 322 | P8-86: Puncture frequency is the determinants of iatrogenic pneumothorax in preoperative pulmonary nodule localization: A propensity matched study
10.1111/resp.14150_598 |
| 322 | P8-87: Clinical study of amrubicin-induced interstitial lung disease in lung cancer patients with interstitial lung abnormality
10.1111/resp.14150_599 |
| 323 | P8-88: The risk of drug-induced interstitial lung disease induced by chemotherapy plus immune checkpoint inhibitors in advanced non-small cell lung cancer with interstitial lung abnormality
10.1111/resp.14150_600 |
| 323 | P8-89: Carcinoid tumors of lung – Diagnosis, treatment and outcomes in a tertiary care centre, INDIA
10.1111/resp.14150_601 |
| 323 | P8-90: An approach to improve the success rate of the oncomine DX target test on lobectomy samples
10.1111/resp.14150_602 |
| 324 | P8-91: Anti-PD-1/PD-L1 antibody plus chemotherapy after platinum-based chemotherapy in patients with advanced non-small cell lung cancer
10.1111/resp.14150_603 |
| 324 | P8-92: Association of PD-L1 expression and density of CT imaging of non-small cell lung cancer: Possible roles of tissue stiffness as a tumor microenvironment
10.1111/resp.14150_604 |
| 325 | P8-93: Relationship between efficacy of afatinib and plasma EGFR mutation in osimertinib-resistant patients with EGFR mutated lung cancer; NJLCG1801B study
10.1111/resp.14150_605 |
| 325 | P8-94: Cross resistance to nab-paclitaxel and other taxanes in non-small cell lung cancer
10.1111/resp.14150_606 |
| 325 | P8-95: Correlation of neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR) and carcinoembryonic antigen (CEA) with overall survival: Review of patients with non-small cell carcinoma (NSCLC) at Ulin General Hospital on period 2017-2019
10.1111/resp.14150_607 |
| 326 | P8-96: The effectiveness of pericardium 6 (PC6) and stomach 36 (ST36) point: Acupressure in the management of acute type nausea and vomiting, anxiety and quality of life of patients undergoing chemotherapy
10.1111/resp.14150_608 |
| 326 | P8-97: Retrospective study of the carcinogenic preventive effect of nintedanib in patients with interstitial pneumonia
10.1111/resp.14150_609 |
| 327 | P8-98: Withdrawn
10.1111/resp.14150_610 |
| 327 | P8-99: Efficacy of repeat re-biopsy and osimertinib in patients with EGFR mutation positive advanced NSCLC
10.1111/resp.14150_611 |
| 327 | P8-100: A case of lung cancer without recurrence for one year despite the absence of treatment after irAE
10.1111/resp.14150_612 |
| 327 | P8-101: EGFR-TKI treatment for squamous cell lung carcinoma with EGFR mutations
10.1111/resp.14150_613 |
| 328 | P8-102: Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab
10.1111/resp.14150_614 |
| 328 | P8-103: Real world long-term survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy
10.1111/resp.14150_615 |
| 329 | P8-104: The clinical outcomes of nivolumab plus ipilimumab combined with platinum-based chemotherapy, single-center, retrospective analysis
10.1111/resp.14150_616 |
| 329 | P8-105: Clinical impact of the modified Glasgow prognostic score in patients diagnosed with advanced non-small cell lung cancer following emergency admission
10.1111/resp.14150_617 |
| 329 | P8-106: Efficacy and safety of atezolizumab plus bevacizumab plus chemotherapy in patients with advanced nonsquamous non-small-cell lung cancer
10.1111/resp.14150_618 |
| 330 | P8-107: Successful treatment with durvalumab, etoposide, and cisplatin in relapsed small cell lung cancer: A case report
10.1111/resp.14150_619 |
| 330 | P8-108: The analysis of genomic profiles of lung cancer with idiopathic pulmonary fibrosis (IPF)
10.1111/resp.14150_620 |
| 331 | P8-109: Prognostic impact and efficacy of neutrophil-to-lymphocyte ratio (NLR) in patients with malignant mesothelioma
10.1111/resp.14150_621 |
| 331 | P8-110: One year survival of advanced lung cancer patients at Sanglah Hospital Denpasar Bali
10.1111/resp.14150_622 |
| 331 | P8-111: Retrospective study of immune checkpoint inhibitors in patients with EGFR mutation-positive lung cancer
10.1111/resp.14150_623 |
| 332 | P8-112: Clinical laboratory result as prognosis marker in advanced stage non-small cell lung cancer (NSCLC) in Indonesia
10.1111/resp.14150_624 |
| 332 | P8-113: Soluble ULBP2 in the sera of patients with EGFR-mutated non-small cell lung cancer
10.1111/resp.14150_625 |
| 332 | P8-114: Impact of clinical features on two-year survival in T790M mutant NSCLC treated with osimertinib
10.1111/resp.14150_626 |
| 333 | P8-115: An extremely rare case of atypical pulmonary carcinoid with possible ectopic insulin production in a 36-year old Filipino
10.1111/resp.14150_627 |
| 333 | P8-116: The clinical efficacy and safety of the second-line chemotherapy in extensive-disease small cell lung cancer patients with interstitial lung disease
10.1111/resp.14150_628 |
| 334 | P8-117: Safety and efficacy of immune checkpoint inhibitors rechallenge in patients with advanced non-small cell lung cancer
10.1111/resp.14150_629 |
| 334 | P8-118: Adenoid cystic carcinoma of the trachea in a patient managed as pulmonary tuberculosis: A case report
10.1111/resp.14150_630 |
| 334 | P8-119: An autopsy case of immune-related severe colitis consequent to long-term treatment with nivolumab in a patient with non-small cell lung cancer
10.1111/resp.14150_631 |
| 335 | P8-120: Therapeutic efficacy of osimertinib following afatinib for the rare EGFR mutation exon19 delL747_P753insS: A case report
10.1111/resp.14150_632 |
| 335 | P8-121: Prognostic effect of cachexia in non-small lung cancer patients receiving immune checkpoint inhibitors
10.1111/resp.14150_633 |
| 336 | P8-122: Comparison of the oncomine Dx target test and the Cobas EGFR mutation detection kit v2 for detecting gene mutations of epidermal growth factor receptor among patients with non-small cell lung cancer: The experience of a single institution
10.1111/resp.14150_634 |
| 336 | P8-123: Case series of Bronchial adenomas treated with cryoablation therapy
10.1111/resp.14150_635 |
| 336 | P8-124: Pierre-Marie-Bamberger syndrome in a patient with a malignant pleural solitary fibrous tumor: A rare case with review of literature
10.1111/resp.14150_636 |
| 337 | P8-125: Proposing clinical prognostic model for 1st line immunotherapy in advanced non-small-cell lung cancer
10.1111/resp.14150_637 |
| 337 | P8-126: High level of C-reactive protein as a predictive and prognostic factor in are pre-immuno treated non-small cell lung cancer patients
10.1111/resp.14150_638 |
| 337 | P8-127: A case of stage iv lung adenocarcinoma with long-term survival for over 18 years, finally found to be positive for EGFR gene mutations
10.1111/resp.14150_639 |
| 338 | P8-128: Phase II trial of pembrolizumab in poor performance status NSCLC patients with PD-L1 ≥ 50%: OLCSG 1801
10.1111/resp.14150_640 |
| 338 | P8-129: Withdrawn
10.1111/resp.14150_641 |
| 338 | P8-130: Diffuse mediastinal edema caused by thoracic lymphoma; a rare cause for superior vena cava narrowing
10.1111/resp.14150_642 |
| 339 | P8-131: Lung cancer that recurred as carcinoma en cuirasse
10.1111/resp.14150_643 |
| 339 | P8-132: The role of caspase-4 in the progression of lung cancer
10.1111/resp.14150_644 |
| 339 | P8-133: Clinical course of the patients who survived more than five-years in patients with EGFR mutated OR ALK rearranged advanced non-small cell lung cancer (NSCLC)
10.1111/resp.14150_645 |
| 340 | P8-134: Bone metastases in malignant pleural mesothelioma
10.1111/resp.14150_646 |
| 340 | P8-135: Typical bronchial carcinoid tumor: A case report
10.1111/resp.14150_647 |
| 341 | P8-136: Nivolumab for malignant mesothelioma: A real-word experience
10.1111/resp.14150_648 |
| 341 | P8-137: Association of immune-related adverse events with therapeutic response to nivolumab in patients with malignant pleural mesothelioma
10.1111/resp.14150_649 |
| 342 | P8-138: A case of successful treatment with dabrafenib and trametinib combination therapy in a patient with recurrent BRAFV600E- mutant non-small-cell lung cancer coexisting radiation pneumonitis
10.1111/resp.14150_650 |
| 342 | P8-139: A case of pulmonary mucoepidermoid carcinoma treated with carboplatin, nab-paclitaxel, and pembrolizumab
10.1111/resp.14150_651 |
| 342 | P8-140: Relationship between response and survival time with immune checkpoint inhibitor combination chemotherapy in advanced non-small cell lung cancer
10.1111/resp.14150_652 |
| 343 | P8-141: Whole-brain radiation therapy for intracranial metastases as initial or late treatment
10.1111/resp.14150_653 |
| 343 | P8-142: A case of pleural mesothelioma with ascites which was well-controlled by GEM plus CPT-11 after the failure of nivolumab treatment
10.1111/resp.14150_654 |
| 343 | P8-143: Clinical impact of post-progression survival on overall survival in NSCLC patients with pre-existing interstitial lung disease
10.1111/resp.14150_655 |
| 344 | P8-144: Prognostic value of neutrophil-to-lymphocyte ratio in patients of malignant pleural mesothelioma treated with nivolumab
10.1111/resp.14150_656 |
| 344 | P8-145: Successful immune checkpoint inhibition in an EGFR-TKI-refractory lung cancer with EGFR mutation and transformation
10.1111/resp.14150_657 |
| 345 | P8-146: Comparison of progression free survival and overall survival between 1st and 2nd generation tyrosine kinase inhibitors as first line therapy for non small cell lung cancer
10.1111/resp.14150_658 |
| 345 | P8-147: Incidence of thromboembolism in lung cancer patients treated with immune checkpoint inhibitors and chemotherapy
10.1111/resp.14150_659 |
| 345 | P8-148: A case of recurrent respiratory papillomatosis with malignant transformation in a young Filipino female presenting as multiple pulmonary nodules
10.1111/resp.14150_660 |
| 346 | P8-149: Lung volume reduction surgery with opportunistic bilateral upper lobe resections for primary synchronous lung cancers: A case report
10.1111/resp.14150_661 |
| 347 | P8-150: Real world study of afatinib and erlotinib as firstline therapy of positive EGFR mutation Javanese lung adenocarcinoma
10.1111/resp.14150_662 |
| 347 | P8-151: Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients
10.1111/resp.14150_663 |
| 347 | P8-152: EBUS and EUS-B in resource-limited settings: a single center experience from Nepal
10.1111/resp.14150_664 |
| 348 | P8-153: Real-data analysis of the combination of an immune checkpoint inhibitor to platinum doublet chemotherapy for small cell lung cancer patients
10.1111/resp.14150_665 |
| 348 | P8-154: Pulmonary epithelioid hemangioendothelioma in adult young man
10.1111/resp.14150_666 |
| 349 | P8-155: Budd–Chiari syndrome caused by a latent hepatic metastasis from a thymoma
10.1111/resp.14150_667 |
| 349 | P8-156: A case of thymic cancer treated with chemotherapy of S-1
10.1111/resp.14150_668 |
| 349 | P8-157: Extraskeletal Ewing sarcoma: A rare cause of primary mediastinal tumour in an elderly
10.1111/resp.14150_669 |
| 350 | P8-158: A case of pulmonary sarcomatoid carcinoma successfully treated with carboplatin + paclitaxel + bevacizumab + atezolizumab
10.1111/resp.14150_670 |
| 350 | P8-159: A rare presentation of respiratory failure with skin involvement in renal transplant recipient
10.1111/resp.14150_671 |
| 351 | P8-160: The steroids worked well on the Steven-Johnson syndrome caused by osimertinib in a patient with EGFR mutation-positive (exon 19 deletion) non-small cell lung cancer
10.1111/resp.14150_672 |
| 351 | P8-161: Curative lobectomy without a preoperative tissue diagnosis in a tuberculosis endemic country: A case report and discussion
10.1111/resp.14150_673 |
| 351 | P8-162: The different in serum calcium levels between bone metastases and no bone metastases lung cancer patients at Dr. Mohammad Hoesin General Hospital in Palembang
10.1111/resp.14150_674 |
| 352 | P8-163: A case report of spontaneous regression of malignant pleural mesothelioma
10.1111/resp.14150_675 |
| 352 | P8-164: Paclitaxel inhibits EGFR-mutated PC9 cell proliferation via the induction of necroptosis and G1 phase arrest
10.1111/resp.14150_676 |
| 352 | P8-165: Paclitaxel induced apoptosis in EGFR-mutated PC9 cells by inhibiting the c-Myc signaling pathway
10.1111/resp.14150_677 |
| 353 | P8-166: A case of meningeal carcinomatosis due to small cell lung cancer triggered by Cauda Equina syndrome
10.1111/resp.14150_678 |
| 353 | P8-167: Sclerosing thymoma: A rare subtype
10.1111/resp.14150_679 |
| 353 | P8-168: A case of MET mutation-positive lung adenocarcinoma in which immune checkpoint inhibitors appear to contribute to long-term survival
10.1111/resp.14150_680 |
| 354 | P8-169: Comparison of the efficacy of gefitinib and afatinib in pulmonary adenocarcinoma therapy with positive EGFR mutations in Javanese race
10.1111/resp.14150_681 |
| 354 | P8-170: A patient with ALK translocation-positive lung adenocarcinoma in whom an EGFR mutation developed during the treatment with ALK inhibitors
10.1111/resp.14150_682 |
| 355 | P8-171: Misdiagnosis of lung cancer and tuberculosis exudative pleurisy
10.1111/resp.14150_683 |
| 355 | P8-172: A retrospective study of the efficacy and safety of nivolumab plus ipilimumab combination therapy for advanced stage non-small cell lung cancer
10.1111/resp.14150_684 |
| 355 | P8-173: The evaluation of the relationship between the plasma concentration and toxicities and effects using divided erlotinib FOR EGFR-mutant NSCLC
10.1111/resp.14150_685 |
| 356 | P8-174: Highly elevated serum levels of CA 19-9 in metastatic adenocarcinoma of the lung
10.1111/resp.14150_686 |
| 356 | P8-175: A retrospective analysis on the lung cancer specimens for oncomine Dx target test in Keio University Hospital
10.1111/resp.14150_687 |
| 356 | P8-176: Synchronous double primary malignancies of the lung and colon presenting with superior vena cava syndrome and colonic obstruction
10.1111/resp.14150_688 |
| 357 | P8-177: Chest wall Ewing's sarcoma – A diagnostic and therapeutic adventure
10.1111/resp.14150_689 |
| 357 | P8-178: Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report
10.1111/resp.14150_690 |
| 358 | P8-179: The inhibitory effect of cisplatin on the growth of A549 cells, and its underlying mechanism
10.1111/resp.14150_691 |
| 358 | P8-180: Growth inhibitory effects of chemotherapeutics drugs in EGFR-mutated PC9 cells during the COVID-19 pandemic
10.1111/resp.14150_692 |
| 358 | P8-181: Comparison between intrathoracic and extra thoracic malignant pleural effusion in clinical features
10.1111/resp.14150_693 |
| 359 | P8-182: Response evaluation criteria in solid tumors (RECIST) in adenocarcinoma lung patients who received EGFR-TKI and chemotherapy in Adam Malik General Hospital Medan
10.1111/resp.14150_694 |
| 359 | P8-183: Giant cell lung carcinoma: A case report
10.1111/resp.14150_695 |
| 359 | P8-184: Clinical analysis of the course of two cases of small cell lung cancer that were difficult to perform bronchoscopy
10.1111/resp.14150_696 |
| 360 | P8-185: Rare case of a posterior mediastinal mass in a 43 year old, male from the Philippines
10.1111/resp.14150_697 |
| 360 | P8-186: Squamous cell carcinoma of lung in non-smoker women
10.1111/resp.14150_698 |
| 360 | P8-187: A case of lung adenocarcinoma with 4.5 years of sustained erlotinib response and reversion of EGFR mutation positiveness
10.1111/resp.14150_699 |
| 361 | P8-188: The inhibitory effect of pemetrexed disodium heptahydrate on the growth of KRAS-dependent A549 cells
10.1111/resp.14150_700 |
| Asthma | |
| 361 | P9-1: Supersulfides are involved in the allergen-induced type 2 airway inflammation through T cell receptor signaling
10.1111/resp.14150_702 |
| 362 | P9-2: Potential mechanisms underlying association between depressive status and asthma
10.1111/resp.14150_703 |
| 362 | P9-3: A RAS inhibitor reduces allergic airway remodeling via regulating IL-33-derived type 2 innate lymphoid cells
10.1111/resp.14150_704 |
| 362 | P9-4: Interim report of a multicenter prospective cohort study of patients with asthma (TNH-AZMA) in Japan
10.1111/resp.14150_705 |
| 363 | P9-5: Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma
10.1111/resp.14150_706 |
| 363 | P9-6: Establishment of a human severe asthma model using humanized mice
10.1111/resp.14150_707 |
| 364 | P9-7: Angiotensin-converting enzyme 2 (ACE2) activator attenuates house dust mite-induced allergic inflammation in mice
10.1111/resp.14150_708 |
| 364 | P9-8: Association between non-contrast chest computed tomography attenuation of lower airway mucus plugs and clinical features in asthmatic patients
10.1111/resp.14150_709 |
| 365 | P9-9: Functional activation of human eosinophils by acetylcholine
10.1111/resp.14150_710 |
| 365 | P9-10: A clinical study of bronchial thermoplasty in the treatment of refractory asthma
10.1111/resp.14150_711 |
| 366 | P9-11: Japanese cedar pollen sublingual immunotherapy for asthma patients with Japanese cedar pollinosis provided stability of symptoms of asthma in the off-season
10.1111/resp.14150_712 |
| 366 | P9-12: TLR7 agonist suppresses type 2 airway inflammation via IL-27-producing interstitial macrophages
10.1111/resp.14150_713 |
| 367 | P9-13: Steroid-resistant airway inflammation in mice induced by chitin
10.1111/resp.14150_714 |
| 367 | P9-14: Genetic liability for insomnia and asthma risk
10.1111/resp.14150_715 |
| 367 | P9-15: Examination of the inflammatory pattern of the bronchi in asthma patients with cold airway hyperresponsiveness with controller antiinflammatory therapy
10.1111/resp.14150_716 |
| 368 | P9-16: High serum EDN levels may be a predictive biomarker for the responsiveness of benralizumab treatment
10.1111/resp.14150_717 |
| 368 | P9-17: Patterns and determinants for longitudinal changes in spirometric parameters among Chinese schoolchildren with asthma
10.1111/resp.14150_718 |
| 369 | P9-18: Effects of one-year of dupilumab treatment in patients with severe asthma
10.1111/resp.14150_719 |
| 369 | P9-19: The usefulness of CT images in evaluating the effects of bronchial thermoplasty in patients with severe asthma
10.1111/resp.14150_720 |
| 369 | P9-20: Respiratory rehabilitation protocol for post-COVID-19 patients with asthma
10.1111/resp.14150_721 |
| 370 | P9-21: Inhaled corticosteroids for all asthma
10.1111/resp.14150_722 |
| 370 | P9-22: Dynamics of asthma control and lung function in patients with stable persistent cold airway hyperresponsiveness
10.1111/resp.14150_723 |
| 371 | P9-23: Prevalence of SABA over-prescription and association with clinical outcomes for asthma management in primary care in the Asian cohort of SABINA III
10.1111/resp.14150_724 |
| 372 | P9-24: Hydrogen sulfide in serum or sputum supernatant as a biomarker for cough reflex sensitivity in patients with asthma
10.1111/resp.14150_725 |
| 372 | P9-25: Usefulness of comprehensive evaluation of spirometry and impulse oscillometry with airway reversibility in the diagnosis of cough variant asthma, bronchial asthma, and asthma-COPD overlap
10.1111/resp.14150_726 |
| 372 | P9-26: Induction of asthma by sensitization to substances derived from periodontal disease bacteria
10.1111/resp.14150_727 |
| 373 | P9-27: Clinical feature and effectiveness of benralizumab therapy for severe asthma
10.1111/resp.14150_728 |
| 373 | P9-28: A comparison of clinical characteristics, between severe asthmatics who continued omalizumab administration and those underwent switch to other biologic agents
10.1111/resp.14150_729 |
| 373 | P9-29: Bone mineral density can be one of the predictors of response to biologics in severe asthma
10.1111/resp.14150_730 |
| 374 | P9-30: Increase in fev1 after dupilumab treatment for refractory asthma is associated with post-treatment eosinophilia
10.1111/resp.14150_731 |
| 374 | P9-31: Dietary habits of adult asthmatics – Internet survey
10.1111/resp.14150_732 |
| 374 | P9-32: Exertional hypoxemia, a potential contributor to activity limitation in patients with asthma
10.1111/resp.14150_733 |
| 375 | P9-33: A study of severe asthma patients who continued omalizumab treatment for more than 3 years
10.1111/resp.14150_734 |
| 375 | P9-34: Seasonal dynamics of cold airway hyperresponsiveness in asthma patients
10.1111/resp.14150_735 |
| 376 | P9-35: Clinical features of patients with bronchial asthma refractory to multiple biological therapies
10.1111/resp.14150_736 |
| 376 | P9-36: Aspergillus sensitization in bronchial asthma; a single centre study in Sri Lanka
10.1111/resp.14150_737 |
| 376 | P9-37: Baseline features and control status of Asian patients with mild asthma in the SYGMA 1 and 2 trials
10.1111/resp.14150_738 |
| 377 | P9-38: The time course of type 2 biomarkers in asthmatics treated with dupilumab
10.1111/resp.14150_739 |
| 378 | P9-39: Efficacy of vitamin d supplementation in children with asthma and vitamin D deficiency: A systematic review
10.1111/resp.14150_740 |
| 378 | P9-40: Study of dysfunctional breathing in patients with bronchial asthma in Japan
10.1111/resp.14150_741 |
| 378 | P9-41: Analysis of benralizumab on humanized IL-33-mediated asthma model
10.1111/resp.14150_742 |
| 379 | P9-42: Impact of an asthma shared care service on hospital attendances and admissions
10.1111/resp.14150_743 |
| 379 | P9-43: Real-world experience of treatment for severe asthma with biologics in single center
10.1111/resp.14150_744 |
| 379 | P9-44: One-year treatment with benralizumab in patients with severe asthma
10.1111/resp.14150_745 |
| 380 | P9-45: Use of smartphone applications in identification of risk factors of asthma attack: A systematic review
10.1111/resp.14150_746 |
| 380 | P9-46: One-year follow-up of instruction in inhalation technique for well-controlled asthma patients
10.1111/resp.14150_747 |
| 381 | P9-47: Increased levels of MMP12 and its clinical significance in induced sputum in asthma patients
10.1111/resp.14150_748 |
| 381 | P9-48: Clinical investigation of serum IL-36 subfamily in patients with asthma
10.1111/resp.14150_749 |
| 381 | P9-49: Involvements of endotoxin in airway inflammation of asthma
10.1111/resp.14150_750 |
| 382 | P9-50: Effect of TRPV2 rs7217735 polymorphism in the development of hypoosmotic airway hyperresponsiveness in asthma patients
10.1111/resp.14150_751 |
| 382 | P9-51: Differences in viral etiology and impact of human rhinovirus c in exacerbations of adult asthma and chronic obstructive pulmonary disease
10.1111/resp.14150_752 |
| 383 | P9-52: Mouthpiece for pressurized metered-dose inhaler (PMDI) to assist in correct inhalation technique
10.1111/resp.14150_753 |
| 383 | P9-53: Establishment of humanized IgE-mediated asthma model
10.1111/resp.14150_754 |
| 383 | P9-54: Association of longitudinal changes in quality of life with comorbidities and exacerbations in patients with severe asthma
10.1111/resp.14150_755 |
| 384 | P9-55: Inhaler techniques and confidence of use of inhalers
10.1111/resp.14150_756 |
| 384 | P9-56: Frequency of biologics use for the treatment of severe asthma in six hospitals in Kanagawa, Japan: A retrospective multi-center retrospective analysis
10.1111/resp.14150_757 |
| 385 | P9-57: A study of severe asthma patients who continued mepolizumab treatment for more than 3 years
10.1111/resp.14150_758 |
| 385 | P9-58: The effect of asthma education program of asthmatic patients
10.1111/resp.14150_759 |
| 385 | P9-59: A forced oscillation technique examination at the start of asthma treatment can be helpful in considering whether DPIs or pMDIs should be selected
10.1111/resp.14150_760 |
| 386 | P9-60: Successful treatment with benralizumab for asthma with eosinophilic myocarditis
10.1111/resp.14150_761 |
| 386 | P9-61: Resolvin E3 dampens asthmatic inflammation in a murine model
10.1111/resp.14150_762 |
| 386 | P9-62: Effectiveness of benralizumab for severe eosinophilic asthma
10.1111/resp.14150_763 |
| 387 | P9-63: Prevalence and clinical relevance of pertussis infection in adult patients with asthma
10.1111/resp.14150_764 |
| 387 | P9-64: The positioning of measurements of serum YKL-40 in patients with ACO
10.1111/resp.14150_765 |
| 388 | P9-65: Analysis of anti-inflammatory effects of Resolvin E3 and its deoxy derivatives
10.1111/resp.14150_766 |
| 388 | P9-66: Retrospective study on the current status and short-term effectiveness of single inhaler triple therapy (SITT) For asthma or asthma and COPD overlap (ACO)
10.1111/resp.14150_767 |
| 388 | P9-67: Adherence to inhaled corticosteroids in working-age patients with asthma: A non-interventional study with secondary use of data
10.1111/resp.14150_768 |
| 389 | P9-68: A trend in use of asthma medications and healthcare resource utilization in moderate-to-severe asthma patients in Japan: A non-interventional study with secondary use of data
10.1111/resp.14150_769 |
| 389 | P9-69: Persistent airway inflammation and airflow limitation in patients with not well-controlled asthma even on ICS/LABA therapy
10.1111/resp.14150_770 |
| 390 | P9-70: The effect of inhalation instruction with wearing masks on therapeutic effect
10.1111/resp.14150_771 |
| 390 | P9-71: Reactivation of asthma into severe uncontrolled symptoms after COVID 19 pneumonia: A case report
10.1111/resp.14150_772 |
| 390 | P9-72: Development and pilot testing of AsmaBoleh: A mobile application to identify the risk factors of asthma attack among Malaysian adults
10.1111/resp.14150_773 |
| 391 | P9-73: Effects of dupilumab for severe eosinophilic asthma COPD overlap
10.1111/resp.14150_774 |
| 391 | P9-74: Analysis of blood plasma 1,2-diacyl phosphatidylcholine molecular species from obese-asthma patients
10.1111/resp.14150_775 |
| 391 | P9-75: Comparative study of the effect of fine-particle size and extrafine particle size inhaled corticosteroid in reducing airway resistance in asthmatic patients
10.1111/resp.14150_776 |
| 392 | P9-76: FP/SALM maintenance plus SABA reliever versus Bud/Form MART regimen in the treatment of uncontrolled asthma in a Philippine government hospital setting: Direct cost comparison
10.1111/resp.14150_777 |
| 392 | P9-77: The correlation of childhood asthma and family history of atopy in Harum Melati clinic, Pringsewu, Lampung, INDONESIA
10.1111/resp.14150_778 |
| 393 | P9-78: Vitamin D binding protein (DBP) in Japanese patients with bronchial asthma
10.1111/resp.14150_779 |
| 393 | P9-79: The relationship between the severity of obstructive sleep apnea and airway hyperreactivity in patients with asthma
10.1111/resp.14150_780 |
| 394 | P9-80: Exposures to cigarette smoke and house dust in relation to child asthma at Harum Melati Clinic, Pringsewu Regency, Lampung, Indonesia
10.1111/resp.14150_781 |
| 394 | P9-81: A case of mepolizumab-tolerant allergic bronchopulmonary aspergillosis successfully switching to benralizumab
10.1111/resp.14150_782 |
| 394 | P9-82: Combination biologic therapy for refractory asthma: A report of two cases
10.1111/resp.14150_783 |
| 395 | P9-83: Assessing peak inspiratory flow rate of patients on dry powdered inhalers using training kits and the in-check dial G16 inspiratory flow meter
10.1111/resp.14150_784 |
| 395 | P9-84: The prevalence of obstructive sleep apnea in Japanese patients with asthma
10.1111/resp.14150_785 |
| 395 | P9-85: The reaction of the pituitary-adrenal system to cold bronchoprovocation in asthma patients with subclinical hypothyroidism
10.1111/resp.14150_786 |
| Respiratory Neurobiology and Sleep | |
| 396 | P10-1: Chronic intermittent hypoxia can induce expression of senescence markers in the liver of C57BL/6J MICE
10.1111/resp.14150_788 |
| 397 | P10-2: Intermittent hypoxia resulted in defective phagocytosis of phagocytes and poorer sepsis outcomes in murine and in vitro study
10.1111/resp.14150_789 |
| 397 | P10-3: Differences between subjective and objective sleep duration according to actual sleep duration and sleep disordered breathing: the Nagahama study
10.1111/resp.14150_790 |
| 398 | P10-4: Clinical study about the safety of orexin receptor antagonist suvorexant for severe sleep apnea syndrome
10.1111/resp.14150_791 |
| 398 | P10-5: Euclidean and geodesic measurements of facial profiles in obstructive sleep apnea
10.1111/resp.14150_792 |
| 398 | P10-6: Determinants of excessive daytime sleepiness in adults with obstructive sleep apnea in Taiwan
10.1111/resp.14150_793 |
| 399 | P10-7: A case of platypnea-orthodeoxia syndrome with sleep apnea syndrome which improved following surgery for her atrial septal defect
10.1111/resp.14150_794 |
| 399 | P10-8: Association between sleep disordered breathing and hemoglobin A1c across antidiabetic treatment; The Nagahama Study
10.1111/resp.14150_795 |
| 400 | P10-9: The role of long-term continuous positive airway pressure in the progression of obstructive sleep apnea: A longitudinal cohort study
10.1111/resp.14150_796 |
| 400 | P10-10: Association between sleep-disordered breathing and chronic spontaneous urticaria
10.1111/resp.14150_797 |
| 400 | P10-11: The effect of body mass index on polysomnographic parameters in adults with obstructive sleep apnea
10.1111/resp.14150_798 |
| 401 | P10-12: Risk factors for poor sleep quality and excessive daytime sleepiness in late pregnancy: A preliminary analysis of a cross-sectional survey
10.1111/resp.14150_799 |
| 402 | P10-13: CIH can induce liver macrophage M2 polarization
10.1111/resp.14150_800 |
| 402 | P10-14: Long term follow-up in pediatric OHS/OSA treated conservatively: Survival tips beyond home ventilation
10.1111/resp.14150_801 |
| 403 | P10-15: The importance of polysomnography screening in bariatric surgery. Sheikh Khaliah Medical City Experience
10.1111/resp.14150_802 |
| 403 | P10-16: A novel mutation in SEPN 1 gene causing rigid spinal muscular dystrophy presenting as diaphragmatic dysfunction and respiratory failure in adulthood
10.1111/resp.14150_803 |
| 404 | P10-17: Idiopathic central alveolar hypoventilation without respiratory failure that required differentiation from obstructive sleep apnea
10.1111/resp.14150_804 |
| 404 | P10-18: Cohort study comparing adherence of fixed and auto-adjusting continuous positive airway pressure (CPAP) in obstructive sleep apnea (OSA) children
10.1111/resp.14150_805 |
| 404 | P10-19: Obstructive sleep apnoea and quality of sleep among general public in Klang, Malaysia
10.1111/resp.14150_806 |
| 405 | P10-20: Sleep and the usage of smart devices among Sri Lankan doctors
10.1111/resp.14150_807 |
| 405 | P10-21: Factors associated with moderate to severe sleep disordered breathing among Filipino school children
10.1111/resp.14150_808 |
| 406 | P10-22: The diagnostic role of portable respiratory monitor in heart failure patient with Cheyne Stoke respiration
10.1111/resp.14150_809 |
| 407 | P10-23: Magnitude of sleep quality and factor associated among undergraduate medical students in Nepal; cross-sectional study
10.1111/resp.14150_810 |
| 407 | P10-24: Successful extubation in a phenobarbital overdose attempted suicide in a non-ideal set-up at the time of COVID 19 pandemic
10.1111/resp.14150_811 |
| Critical Care Medicine | |
| 407 | P11-1: The therapeutic effects of lactoferrin on thioacetamide-induced liver fibrosis in rats
10.1111/resp.14150_813 |
| 408 | P11-2: Clinical profiles and respiratory system mechanics of mechanically ventilated patients with COVID-19 versus non-COVID-19-associated ARDS
10.1111/resp.14150_814 |
| 408 | P11-3: The risk of suicide in critical illness patients- the known, the unknown, and the unknowable
10.1111/resp.14150_815 |
| 409 | P11-4: Delayed cardiovascular events and one-year mortality among intensive care unit (ICU) sepsis survivors
10.1111/resp.14150_816 |
| 409 | P11-5: Clinical outcomes of hypoxemic, COVID-19 confirmed patients on high-flow nasal cannula (HFNC) therapy in a tertiary government hospital in Metro Manila, Philippines: A retrospective study
10.1111/resp.14150_817 |
| 409 | P11-6: Indices of endogenous intoxication in patients with COVID-19 associated pneumonia
10.1111/resp.14150_818 |
| 410 | P11-7: Issues related to ECMO management in critically ill patients with COVID-19: A systematic review and meta-analysis
10.1111/resp.14150_819 |
| 410 | P11-8: Surviving covid: A case report on the first covid survivor after extracorporeal membrane oxygenation (ECMO) in the Philippines
10.1111/resp.14150_820 |
| 410 | P11-9: Vanishing lung syndrome mimicking spontaneous pneumothorax: A case report and literature review
10.1111/resp.14150_821 |
| 411 | P11-10: Application of high-flow nasal oxygen (HFNC) for acute exacerbations of interstitial lung diseases. experiences from National Lung Hospital, Vietnam
10.1111/resp.14150_822 |
| 412 | P11-11: Bilateral iliopsoas hematomas in a severe COVID-19 patient treated with unfractionated heparin: A case report and review of literature
10.1111/resp.14150_823 |
| 412 | P11-12: A tale of ice and fire: Dexmedetomidine-induced hyperthermia after complex coronary artery revascularization for cardiogenic shock
10.1111/resp.14150_824 |
| 413 | P11-13: Diffuse pulmonary hemorrhage, a catastrophic outcome of a 57-year-old venezuelan, with COVID-19 pneumonia, who developed multiple thrombosis and aman-variant GBS
10.1111/resp.14150_825 |
| 413 | P11-14: Blood gas analysis and alveolar-arterial gradient as predictor of mortality confirmed COVID-19 patients outcome in Tertiary Referral Hospital
10.1111/resp.14150_826 |
| 413 | P11-15: Use of intravenous immunoglobulin in Streptococcus dysgalactiae associated toxic shock syndrome
10.1111/resp.14150_827 |
| 414 | P11-16: Intubation and artificial ventilation treatment for elderly patients with respiratory failure
10.1111/resp.14150_828 |
| 414 | P11-17: Outcomes of COVID 19 critical care patients in Indonesia periphery
10.1111/resp.14150_829 |
| Bronchoscopy and Interventional Techniques | |
| 415 | P12-1: Fixation rate of gold markers placed for stereotactic body radiotherapy in each bronchus
10.1111/resp.14150_831 |
| 415 | P12-2: A comparison of radial endobronchial ultrasound (R-EBUS) guided cryobiopsy and forceps biopsies for lung nodules: An Australian perspective
10.1111/resp.14150_832 |
| 415 | P12-3: Diagnostic efficacy of cryobiopsy for peripheral pulmonary lesions with ground-glass opacity: A propensity score-matched analysis
10.1111/resp.14150_833 |
| 416 | P12-4: Interventional pulmonology for elderly patients with malignant central airway obstruction
10.1111/resp.14150_834 |
| 416 | P12-5: Correlation between bispectral index (BIS) and modified observer's assessment of alertness/sedation (MOAA/S) score in flexible bronchoscopy
10.1111/resp.14150_835 |
| 417 | P12-6: Endobronchial and pleural cryobiopsy for pulmonary malignancy
10.1111/resp.14150_836 |
| 417 | P12-7: Preoperative chest CT localization under different positions with appropriate amount of air in the pleural space for the evaluation of bullae related to spontaneous pneumothorax
10.1111/resp.14150_837 |
| 417 | P12-8: New style for bronchoscopy to prevent infection under COVID-19 pandemic
10.1111/resp.14150_838 |
| 418 | P12-9: Predictive risk factors for pneumothorax after transbronchial biopsy using endobronchial ultrasonography with a guide sheath
10.1111/resp.14150_839 |
| 418 | P12-10: Additional use of propofol during flexible bronchoscopy in difficult-to-sedate cases with transcutaneous blood gas monitoring, anesthetized with midazolam and fentanyl: A retrospective study
10.1111/resp.14150_840 |
| 419 | P12-11: Routine gargling before bronchoscopy for prevention of post-bronchoscopic infection
10.1111/resp.14150_841 |
| 419 | P12-12: Bronchoscopy with n-acetylcysteine lavage in a COVID-19 patient with massive grade IV inhalation injury
10.1111/resp.14150_842 |
| 420 | P12-13: Characteristics of visible leak under medical thoracoscopy in persistent pneumothorax
10.1111/resp.14150_843 |
| 420 | P12-14: The accuracy of rapid on-site cytologic evaluation (ROSE) in bronchoscopy
10.1111/resp.14150_844 |
| 420 | P12-15: Comparison of EBUS/TBNA specimen adequacy of tissue-clot-coagulum cell block versus normal saline rinse cytology
10.1111/resp.14150_845 |
| 421 | P12-16: The feasibility and safety of transbronchial cryobiopsy using a 2-scope technique in peripheral pulmonary lesions
10.1111/resp.14150_846 |
| 421 | P12-17: Clinical significance of bronchoscopy in elderly patients with lung cancer
10.1111/resp.14150_847 |
| 422 | P12-18: Comparison between manual vs other techniques of pleural fluid evacuation during thoracentesis: A meta-analysis
10.1111/resp.14150_848 |
| 422 | P12-19: Cryptogenic hemoptysis in smokers: Clinical characteristics, CT, angiography and prognosis after bronchial artery embolization using coils in 60 patients
10.1111/resp.14150_849 |
| 423 | P12-20: A prospective observational study on the tolerability of nasal bronchoscopy with surgical mask for aerosol control
10.1111/resp.14150_850 |
| 423 | P12-21: The recommended image features of peripheral lung parenchymal targets for diagnosis by CT-guided needle biopsy
10.1111/resp.14150_851 |
| 423 | P12-22: Three-dimensional printing of reconstructed airway model for complex post tuberculous tracheobronchial stenosis
10.1111/resp.14150_852 |
| 424 | P12-23: Bronchial artery embolization in patients with hemoptysis: self-assessed patents satisfaction with treatment, efficacy, safety, and quality of life
10.1111/resp.14150_853 |
| 424 | P12-24: Tracheo- bronchial stenosis- different clinical presentations and individualised treatment approach
10.1111/resp.14150_854 |
| 425 | P12-25: Optimal midazolam dose for bronchoscopy in elderly patients based on changes in respiratory parameters
10.1111/resp.14150_855 |
| 425 | P12-26: Isolated mediastinal lymphadenopathy - A great deception
10.1111/resp.14150_856 |
| 426 | P12-27: Bronchoscopy under non-invasive ventilation therapy
10.1111/resp.14150_857 |
| 426 | P12-28: Bronchiolitis obliterans after bone marrow transplantation diagnosed by ultrathin bronchoscopy: A case report
10.1111/resp.14150_858 |
| 427 | P12-29: Diagnostic value and correlation between findings on pleuroscopy and histopathological diagnosis in patients with pleural effusion: A 3 years retrospective study
10.1111/resp.14150_859 |
| 428 | P12-30: Double stenting in bronchoesophageal fistula: A case report
10.1111/resp.14150_860 |
| 428 | P12-31: Macroscopical and pathological findings by thoracoscopy under local anesthesia in malignant pleural mesothelioma
10.1111/resp.14150_861 |
| 429 | P12-32: Cryo-recanalization in a case of recurrent endobronchial diffuse large B-cell lymphoma
10.1111/resp.14150_862 |
| 429 | P12-33: Endobronchial carcinoid mimicking bronchial asthma
10.1111/resp.14150_863 |
| 430 | P12-34: Broncholithiasis successfully removed using a cryo-probe under rigid bronchoscopy: A case report
10.1111/resp.14150_864 |
| 430 | P12-35: Role of bronchoscopy in centrally-located lung tumor
10.1111/resp.14150_865 |
| 431 | P12-36: Bronchoscopic cryo-excision of a large chondroid hemartoma presented as right middle lobe collapse in a 63 yrs gentleman
10.1111/resp.14150_866 |
| 431 | P12-37: Tracheobronchopathia osteochondroplastica associated with lung adenocarcinoma: A rare in rare presentation
10.1111/resp.14150_867 |
| 432 | P12-38: A young woman with bilateral primary spontaneous pneumothorax
10.1111/resp.14150_868 |
| Paediatric Lung Disease | |
| 432 | P13-1: Chest X-ray findings of coronavirus-19 disease in patients age 0 to 18 years old admitted at Chong Hua Hospital from March 2020 to February 2021
10.1111/resp.14150_870 |
| 432 | P13-2: The effect of vitamin D on the course of COVID-19 in children
10.1111/resp.14150_871 |
| 433 | P13-4: Congenital cystic adenomatoid malformation (CCAM) OF the lung in a teenager: A case report
10.1111/resp.14150_873 |
| 433 | P13-5: Primary spontaneous pneumothorax in children: Causes or not ?
10.1111/resp.14150_874 |
| Respiratory Structure and Function | |
| 434 | P14-1: Long-acting muscarinic antagonists enhance ciliary function in airway epithelium
10.1111/resp.14150_876 |
| 434 | P14-2: Sex differences in airway and lung sizes on CT in healthy non-smokers with normal spirometry
10.1111/resp.14150_877 |
| 435 | P14-3: Relationship between gait asymmetry and respiratory muscle strength in the stroke patients
10.1111/resp.14150_878 |
| 435 | P14-4: Thoracic kidney: A rare form of renal ectopia
10.1111/resp.14150_879 |
| 436 | P14-5: A method of analysis of pulmonary function by movement of the left and right lungs using a three dimensional depth sensor
10.1111/resp.14150_880 |
| 436 | P14-6: Associations between extrapulmonary airway to lung size ratio and forced expiratory airflow in smokers with and without chronic obstructive pulmonary disease and healthy non-smokers
10.1111/resp.14150_881 |
| 436 | P14-7: Restrictive spirometry pattern and the risk of rapid kidney function decline: Analysis From the community-based prospective Ansan-Ansung cohort in Korea
10.1111/resp.14150_882 |
| 437 | P14-8: Intralobar pulmonary sequestration with significantly elevated CA 19-9 level: A case report
10.1111/resp.14150_883 |
| 438 | P14-9: Lung function analysis of COVID-19 survivors in dr. Zainoel Abidin Hospital Banda Aceh, Indonesia
10.1111/resp.14150_884 |
| 438 | P14-10: Sniff nasal inspiratory pressure in healthy laboratory staff
10.1111/resp.14150_885 |
| 438 | P14-11: Impulse oscillometry test quality in a clinical laboratory
10.1111/resp.14150_886 |
| 439 | P14-12: A case report of tracheal bronchus associated with Koch's disease in a 7 month old female with down syndrome
10.1111/resp.14150_887 |
| 439 | P14-13: Correlation of airway hyperresponsiveness with peripheral blood eosinophilia by histamine challenge in young adult patients with chronic cough
10.1111/resp.14150_888 |
| 439 | P14-14: Preoperative examination as predictor of postoperative pulmonary complication in abdominal surgery
10.1111/resp.14150_889 |
| 440 | P14-15: Pleural effusion secondary to left atrial myxoma in a 36 year old Chinese male
10.1111/resp.14150_890 |
| Pulmonary Circulation | |
| 440 | P15-1: Risk assessment in pulmonary hypertension due to interstitial lung disease
10.1111/resp.14150_892 |
| 441 | P15-2: Activation of cleaved caspase-3 in young rats of emphysema with pulmonary hypertension induced by SU5416
10.1111/resp.14150_893 |
| 441 | P15-3: Potential amelioration of pulmonary hypertension in COPD by budesonide/glycopyrronium/formoterol via central NFκB inflammatory signaling deactivation: In vivo mouse model
10.1111/resp.14150_894 |
| 442 | P15-4: Pulmonary vasculopathy in pulmonary hypertension with interstitial lung disease: A morphometric study of autopsy cases
10.1111/resp.14150_895 |
| 442 | P15-5: Diagnosis of platypnea-orthodeoxia syndrome secondary to an intracardiac shunt following the development of organizing pneumonia: A case report
10.1111/resp.14150_896 |
| 443 | P15-6: Analysis of %FVC/%DLCO ratio for pulmonary hypertension associated with interstitial lung disease
10.1111/resp.14150_897 |
| 443 | P15-7: Bosentan has potential benefits in patients with exercise OR mild-to-moderate pulmonary hypertension associated with COPD
10.1111/resp.14150_898 |
| 443 | P15-8: Dasatinib induced pulmonary arterial hypertension and pleural effusion in post allogenic stem cell transplant cml patient
10.1111/resp.14150_899 |
| 444 | P15-9: A case report on pulmonary hypertension in pregnancy
10.1111/resp.14150_900 |
| 444 | P15-10: A rare case of May-Thurner syndrome presenting as venous thromboembolism: A case report
10.1111/resp.14150_901 |
| 445 | P15-11: Prognostic analysis of pulmonary hypertension with parenchymal lung lesion-comparison of connective tissue disease and chronic lung disease
10.1111/resp.14150_902 |
| 445 | P15-12: Pulmonary artery pseudoaneurysms: 3 cases examined and treated at the National Lung Hospital, Hanoi, Vietnam
10.1111/resp.14150_903 |
| 445 | P15-13: Pulmonary arteriovenous malformations presenting as a fatal hemorrhage: A case report
10.1111/resp.14150_904 |
| 446 | P15-14: Management of pulmonary embolism in an Australian Tertiary Centre
10.1111/resp.14150_905 |
| 446 | P15-15: A rare case of bilateral chylothorax and chylous ascites in diffuse large beta cell non-hodgkin's lymphoma
10.1111/resp.14150_906 |
| 446 | P15-16: Modified dose thrombolysis in a COVID-19 related massive acute pulmonary embolism: A case report
10.1111/resp.14150_907 |
| 447 | P15-17: Proportion of pulmonary hypertension in drug resistant tuberculosis patient
10.1111/resp.14150_908 |
| Interstitial Lung Disease | |
| 447 | P16-1: Verifying performance of the deep learning algorism to detect chronic fibrosing interstitial lung diseases on chest radiograph: Assessment of detectability in each disease type
10.1111/resp.14150_910 |
| 448 | P16-2: Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody
10.1111/resp.14150_911 |
| 448 | P16-3: THE roles of angiopoietin-like 4 in lung fibrosis
10.1111/resp.14150_912 |
| 449 | P16-4: Therapeutic effect of oligonucleotide therapeutics PK-7010 in mouse model of bleomycin-induced lung fibrosis
10.1111/resp.14150_913 |
| 449 | P16-5: Evaluation of pulmonary artery vasculopathy in patients WITH IPF
10.1111/resp.14150_914 |
| 450 | P16-6: Analysis of anti-fibrotic potential of JAK inhibitors in bleomycin-induced pulmonary fibrosis model
10.1111/resp.14150_915 |
| 450 | P16-7: Radiological unilateral pleuroparenchymal fibroelastosis as a notable late complication after lung cancer surgery
10.1111/resp.14150_916 |
| 451 | P16-9: Gremlin-1 for the differential diagnosis of idiopathic pulmonary fibrosis versus other interstitial lung diseases
10.1111/resp.14150_918 |
| 451 | P16-10: Usefulness of plasma and urine lysophospholipids-producing enzymes as a prognostic marker for sarcoidosis
10.1111/resp.14150_919 |
| 452 | P16-11: Atypical radiologic computed tomography appearances of the chest in patients with lymphangioleiomyomatosis
10.1111/resp.14150_920 |
| 452 | P16-12: Key findings of the Fukuoka tobacco-related lung disease (FOLD) registry study in Japan
10.1111/resp.14150_921 |
| 453 | P16-13: Bronchial epithelial cell-derived extracellular vesicles attenuate pulmonary fibrosis targeting TGF-Β-WNT crosstalk
10.1111/resp.14150_922 |
| 453 | P16-14: Iron-dependent mitochondrial dysfunction contributes to the pathogenesis of pulmonary fibrosis
10.1111/resp.14150_923 |
| 454 | P16-15: Predictive factors for relapse in corticosteroid-treated patients with chronic eosinophilic pneumonia
10.1111/resp.14150_924 |
| 454 | P16-16: The role of statins on the risk of the cancer among the interstitial lung diseases and pulmonary fibrosis: A time-dependent in propensity-matched general population study focus on the immunologic cancer
10.1111/resp.14150_925 |
| 454 | P16-17: Clinical characteristics of drug-induced interstitial pneumonia in Japan
10.1111/resp.14150_926 |
| 455 | P16-18: Role of IGF-1 in idiopathic pulmonary fibrosis: analysis of patient lung specimens
10.1111/resp.14150_927 |
| 455 | P16-19: Efficacy and safety of tacrolimus for fibrotic hypersensitivity pneumonitis
10.1111/resp.14150_928 |
| 456 | P16-20: Database analysis of hypersensitivity pneumonitis in Japan
10.1111/resp.14150_929 |
| 456 | P16-21: Clinical course and outcomes of acute exacerbation of fibrosing interstitial lung disease; a multicenter retrospective cohort study
10.1111/resp.14150_930 |
| 456 | P16-22: Clinical characteristics in patients with asymmetric fibrotic hypersensitivity pneumonitis
10.1111/resp.14150_931 |
| 457 | P16-23: Polo-like kinase inhibitors identified by computational repositioning attenuates bleomycin-induced pulmonary fibrosis in mice
10.1111/resp.14150_932 |
| 457 | P16-24: Clinical impact of sarcopenia on chemotherapy-triggered exacerbation of interstitial lung disease in patients with non-small cell lung cancer
10.1111/resp.14150_933 |
| 458 | P16-25: Effects of statins and steroids on stroke and coronary artery disease among patients with interstitial lung disease and pulmonary fibrosis: A general population study
10.1111/resp.14150_934 |
| 458 | P16-26: Assessment of diagnostic accuracy of serum hemeoxygenase-1 measurement for acute exacerbation of interstitial lung disease
10.1111/resp.14150_935 |
| 458 | P16-27: A deep learning approach using chest X-ray data for screening drug-induced interstitial lung disease
10.1111/resp.14150_936 |
| 459 | P16-28: CD38+ HLA-DR− helper T lymphocytes are associated with immune checkpoint inhibitors-related interstitial pneumonia
10.1111/resp.14150_937 |
| 459 | P16-29: The attempt to establish the disease prognosis prediction model using Charlson Comorbidity Index Score in interstitial lung disease
10.1111/resp.14150_938 |
| 460 | P16-30: Serum hemeoxygenase-1 as the potential biomarker for acute exacerbation of fibrosing interstitial lung disease
10.1111/resp.14150_939 |
| 460 | P16-31: Pulmonary manifestation of anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
10.1111/resp.14150_940 |
| 461 | P16-32: Charlson Comorbidity Index Score could not influence the duration and efficacy of antifibrotic treatment for idiopathic pulmonary fibrosis (real world cohort data in 131 patients)
10.1111/resp.14150_941 |
| 461 | P16-33: Real world experience of the antifibrotic treatment for idiopathic pulmonary fibrosis (166 patients)
10.1111/resp.14150_942 |
| 462 | P16-34: Clinical investigation of the relationship between interstitial lung disease and obstructive sleep apnea
10.1111/resp.14150_943 |
| 462 | P16-35: Lung infiltration of immunoglobulin g1- and G4-positive cells is a prognostic marker for idiopathic interstitial pneumonias
10.1111/resp.14150_944 |
| 463 | P16-36: A LCK-specific inhibitor, A-770041, attenuates pulmonary fibrosis via the suppression of TGF-B production in regulatory T cells
10.1111/resp.14150_945 |
| 463 | P16-37: Effect of autophagy in human alveolar epithelial cells on pulmonary fibrosis
10.1111/resp.14150_946 |
| 463 | P16-38: The phosphate binder attenuates microlith formation and COX-2 induction in pulmonary alveolar microlithiasis
10.1111/resp.14150_947 |
| 464 | P16-39: Identification of targetable kinases in idiopathic pulmonary fibrosis
10.1111/resp.14150_948 |
| 465 | P16-40: Survey of nursing practice by nurses specializing in respiratory care for Japanese idiopathic pulmonary fibrosis patients -comparison by background
10.1111/resp.14150_949 |
| 465 | P16-41: post-marketing surveillance (all-case surveillance) of nintedanib in Japanese patients with idiopathic pulmonary fibrosis (4th interim report)
10.1111/resp.14150_950 |
| 465 | P16-42: Clinical characteristics of obstructive sleep apnea in Japanese idiopathic pulmonary fibrosis patients
10.1111/resp.14150_951 |
| 466 | P16-43: Development of ILD-GAP scoring system using Charlson Comorbidity Index Score in patients with interstitial lung diseases
10.1111/resp.14150_952 |
| 466 | P16-44: Unbiased retrospective survey of ‘real-world data’ generated a 1,000-case new cohort of interstitial lung diseases
10.1111/resp.14150_953 |
| 467 | P16-45: Efficacy of multidisciplinary discussion (MDD) with transbronchial lung cryobiopsy
10.1111/resp.14150_954 |
| 467 | P16-46: Sarcoid-like reaction in patients with malignant solid-tumor: long term clinical course and outcome
10.1111/resp.14150_955 |
| 8 | P16-47: A study of lymphocyte fraction in bronchoalveolar lavage fluid in interstitial lung disease
10.1111/resp.14150_956 |
| 468 | P16-48: The prognostic marker of polymyxin B-immobilized fiber column-direct hemoperfusion in patients who developed acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia
10.1111/resp.14150_957 |
| 469 | P16-49: Analysis of lymphocyte fractions in bronchoalveolar lavage fluid in chronic eosinophilic pneumonia
10.1111/resp.14150_958 |
| 469 | P16-50: Clinical features of pleuroparenchymal fibroelastosis: Idiopathic versus secondary phenotype
10.1111/resp.14150_959 |
| 469 | P16-51: Lung sound analysis for idiopathic pulmonary fibrosis patients using an electronic stethoscope
10.1111/resp.14150_960 |
| 470 | P16-52: Clinical significance of Charlson Comorbidity Index as a prognostic parameter for patients with acute exacerbation of interstitial pneumonia
10.1111/resp.14150_961 |
| 470 | P16-53: Effectiveness of antifibrotic treatment for acute exacerbation of idiopathic pulmonary fibrosis
10.1111/resp.14150_962 |
| 471 | P16-54: Association between efficacy of antifibrotic agents and immunohistochemical localization of fibrotic factors in progressive fibrosing interstitial lung disease
10.1111/resp.14150_963 |
| 471 | P16-55: Additional effects of macrolides on steroid pulse therapy in patients with acute exacerbation of interstitial lung disease
10.1111/resp.14150_964 |
| 472 | P16-56: The effect of pulmonary macrophage transplantation on mice with bleomycin-induced pulmonary fibrosis
10.1111/resp.14150_965 |
| 472 | P16-57: RANKL-dependent pulmonary fibrosis in the silicosis model mouse
10.1111/resp.14150_966 |
| 473 | P16-58: Low BMI is associated with poor prognosis in patients with IPF who were incidentally diagnosed
10.1111/resp.14150_967 |
| 473 | P16-59: Clinical significance of serum heart-type fatty acid-binding protein (H-FABP) in acute exacerbation of idiopathic interstitial pneumonias
10.1111/resp.14150_968 |
| 473 | P16-60: Post COVID-19 organizing pneumonia treated with mycophenolate mofetil
10.1111/resp.14150_969 |
| 474 | P16-61: Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain
10.1111/resp.14150_970 |
| 474 | P16-62: The prognostic factor of idiopathic interstitial pneumonias patients complicated with pneumothorax: A multicenter retrospective study
10.1111/resp.14150_971 |
| 474 | P16-63: Efficacy of high- versus low-dose corticosteroid therapy in patients with acute exacerbation of idiopathic interstitial pneumonia: A nationwide observational study
10.1111/resp.14150_972 |
| 475 | P16-64: Safety of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with interstitial lung abnormalities or interstitial lung disease
10.1111/resp.14150_973 |
| 475 | P16-65: Relationship between size and morphology of alveolar macrophages in bronchoalveolar lavage fluid in sarcoidosis
10.1111/resp.14150_974 |
| 476 | P16-66: Differences in prognosis by etiology among patients with chronic fibrosing idiopathic interstitial pneumonias with acute exacerbation
10.1111/resp.14150_975 |
| 476 | P16-67: Kinetic changes of serum KL-6 levels predict disease progression in systemic sclerosis-associated interstitial lung disease
10.1111/resp.14150_976 |
| 477 | P16-68: Clinical, radiological and pathological differences between humidifier lung and summer-type hypersensitivity pneumonitis
10.1111/resp.14150_977 |
| 477 | P16-69: Assessment of the effect of endothelin receptor antagonist in patients with less severe or severe pulmonary hypertension associated with interstitial lung disease
10.1111/resp.14150_978 |
| 478 | P16-70: Clinical value of 18F-FDG PET/CT For acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease after lung resection
10.1111/resp.14150_979 |
| 478 | P16-71: Factors associated with pulmonary function decline in patients with rheumatoid arthritis-associated interstitial lung disease
10.1111/resp.14150_980 |
| 479 | P16-72: Effects of nintedanib on forced vital capacity categorical changes and disease progression in Japanese patients with progressive fibrosing interstitial lung diseases: subanalysis of inbuild study
10.1111/resp.14150_981 |
| 479 | P16-73: Prognostic significance of serum serological and radiological findings in idiopathic chronic fibrosing interstitial pneumonia
10.1111/resp.14150_982 |
| 480 | P16-74: A retrospective study to evaluate the prevalence, aetiologies and types of interstitial lung disease (ILD) at University Malaya Medical Centre from 2010 to 2020
10.1111/resp.14150_983 |
| 480 | P16-75: Traction bronchiectasis on conventional chest computed tomography is a prognostic factor for rheumatoid arthritis-related interstitial lung disease
10.1111/resp.14150_984 |
| 481 | P16-76: Evaluation of exercise capacity in patients with interstitial lung disease by dynamic-ventilatory digital radiography
10.1111/resp.14150_985 |
| 481 | P16-77: Factors associated with interstitial lung disease in patients with rheumatoid arthritis (RA-ILD): Experience from a rheumatology-respiratory centre in Malaysia
10.1111/resp.14150_986 |
| 482 | P16-78: Early tapering of corticosteroid in patients with acute exacerbation of idiopathic pulmonary fibrosis: Retrospective analyses of multi-center cohort and administrative data
10.1111/resp.14150_987 |
| 482 | P16-79: The tolerability and efficacy of long-term nintedanib treatment for idiopathic pulmonary fibrosis in the real-world
10.1111/resp.14150_988 |
| 482 | P16-80: Differential source of early phase discontinuation between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
10.1111/resp.14150_989 |
| 483 | P16-81: The effects of fluoroquinolones on the risk of cancer in patients with interstitial disease and pulmonary fibrosis
10.1111/resp.14150_990 |
| 483 | P16-82: Health-related quality of life in patients with idiopathic pulmonary fibrosis treated with nintedanib
10.1111/resp.14150_991 |
| 484 | P16-83: HRCT scoring focused on ground-glass opacity, perilobular opacity, airspace consolidation, and interlobular septal thickening is useful for interstitial lung disease accompanied by anti-MDA5 antibody-positive dermatomyositis
10.1111/resp.14150_992 |
| 484 | P16-84: The relationship between the treatment dose and survival of patients with interstitial pneumonia treated with pirfenidone
10.1111/resp.14150_993 |
| 485 | P16-85: Differences in the therapeutic effects of corticosteroid and immunosuppressants between the two subtypes of systemic sclerosis-associated interstitial lung disease
10.1111/resp.14150_994 |
| 485 | P16-86: Tolerability and safety of nintedanib for idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases
10.1111/resp.14150_995 |
| 485 | P16-87: Cryptogenic organizing pneumonia: Real-world experience of treatment with corticosteroid
10.1111/resp.14150_996 |
| 486 | P16-88: Real world multicenter prospective study of combination therapy of anti-fibrotic agents in idiopathic pulmonary fibrosis (J-avengers): An interim analysis
10.1111/resp.14150_997 |
| 485 | P16-89: Comparison of clinical features between the high and low serum KL-6 patients with acute exacerbation of interstitial lung diseases
10.1111/resp.14150_998 |
| 487 | P16-90: Clinical comparison of patients with acute exacerbation of idiopathic interstitial pneumonias and secondary interstitial pneumonias
10.1111/resp.14150_999 |
| 487 | P16-91: Idiopathic pulmonary fibrosis patients having refractory cough have bronchiectasis and airway architectural distortion: a single center retrospective study
10.1111/resp.14150_1000 |
| 488 | P16-92: The CT extent of honeycomb cannot predict the treatment outcome of the patients with acute exacerbation of interstitial lung disease
10.1111/resp.14150_1001 |
| 489 | P16-93: Preliminary analysis of serum risk factors during an acute exacerbation of chronic fibrosing interstitial pneumonia: A multi-institutional prospective study
10.1111/resp.14150_1002 |
| 489 | P16-94: Characteristics of connective tissue diseases associated interstitial lung diseases-A single centre study in Sri Lanka
10.1111/resp.14150_1003 |
| 489 | P16-95: High incidence of MPO-ANCA positive interstitial pneumonia during the COVID-19 pandemic
10.1111/resp.14150_1004 |
| 490 | P16-96: Efficacy and safety of combination therapy of antifibrotic agents in patients with idiopathic pulmonary fibrosis
10.1111/resp.14150_1005 |
| 490 | P16-97: Secondary organizing pneumonia following COVID-19 infection
10.1111/resp.14150_1006 |
| 491 | P16-98: Investigation of predictive biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib
10.1111/resp.14150_1007 |
| 491 | P16-99: Diffuse pulmonary ossification diagnosed pathologically: A four case series
10.1111/resp.14150_1008 |
| 491 | P16-100: A rare case of vertebral sarcoidosis
10.1111/resp.14150_1009 |
| 492 | P16-101: Pulmonary actinomycosis: An opportunistic infection in pulmonary alveolar proteinosis
10.1111/resp.14150_1010 |
| 492 | P16-102: Five cases of interstitial lung disease with organizing pneumonia pattern that appeared during treatment of ulcerative colitis
10.1111/resp.14150_1011 |
| 493 | P16-103: Case series of cryptogenic organising pneumonia masquerading as tuberculosis (TB) in a TB endemic area
10.1111/resp.14150_1012 |
| 493 | P16-104: A case of IgG4-related lung disease diagnosed during a routine medical checkup
10.1111/resp.14150_1013 |
| 494 | P16-105: A case of pulmonary amyloidosis associated with systemic lupus erythematosus
10.1111/resp.14150_1014 |
| 494 | P16-106: A rare case of dapsone induced eosinophilic pneumonia
10.1111/resp.14150_1015 |
| 495 | P16-107: A case report of rare disease: Pulmonary alveolar microliathitis
10.1111/resp.14150_1016 |
| 495 | P16-108: When you lose the way, history leads it!
10.1111/resp.14150_1017 |
| 496 | P16-109: Vaping induced non-specific interstitial pneumonia – A rarely described entity
10.1111/resp.14150_1018 |
| 496 | P16-110: THE co-relation between exercise capacity and pulmonary hypertension in different types of interstitial lung diseases in a Tertiary Care Center in India
10.1111/resp.14150_1019 |
| 496 | P16-111: Pneumothorax with rapid progression of respiratory failure secondary to pulmonary fibrosis in Hermansky-Pudlak syndrome: A case report
10.1111/resp.14150_1020 |
| 497 | P16-112: A case of pulmonary langerhans cell histiocytosis (PLCH) presenting as massive hemoptysis
10.1111/resp.14150_1021 |
| 498 | P16-113: Organizing pneumonia in a post-partum mother; a rare presentation of SLE
10.1111/resp.14150_1022 |
| 498 | P16-114: Unexplained cachexia due to pleuropulmonary fibroelastosis of the lung – An old lady's agony
10.1111/resp.14150_1023 |
| 499 | P16-115: Sarcoidosis causing obliterative bronchiolitis –An unexplained entity
10.1111/resp.14150_1024 |
| 499 | P16-116: Elusive lung adenocarcinoma in systemic sclerosis with non specific interstitial pneumonia
10.1111/resp.14150_1025 |
| 500 | P16-117: A breathless man with a “sandstorm” appearance on lung computed tomography
10.1111/resp.14150_1026 |
| 500 | P16-118: Vonoprazan-induced interstitial pneumonitis: A case report
10.1111/resp.14150_1027 |
| 500 | P16-119: A case of interstitial pneumonia with lung lesion-preceding ANCA-related vasculitis improved after 7 years without treatment
10.1111/resp.14150_1028 |
| 501 | P16-120: Pleuroparenchymal fibroelastosis, a rare idiopathic interstitial pneumonia with distinct clinical, radiological and pathological features
10.1111/resp.14150_1029 |
| 501 | P16-121: Chronic eosinophilic pneumonia as a cause for progressive fibrotic lung diseases – A rare entity
10.1111/resp.14150_1030 |
| Author Index | |
| 503 | Author Index |
Respirology
 |
Volume 26 Supplement Issue s3 November 2021 |
 |
| The 25th Congress of the Asian Pacific Society of Respirology (APSR 2021) Hybrid – In person and Virtual, 20‐21 November 2021, Kyoto |
||
| Index | Submit an article |
About Respirology |
Read this issue's articles |
